
--- Page 5 ---
incredible heritage that today includes our 
incredible heritage that today includes our 
incredible heritage that today includes our
incredible heritage that today includes our 
leadership in minimally invasive surgery and 
leadership in minimally invasive surgery and
leadership in minimally invasive surgery and 
leadership in minimally invasive surgery and 
innovatively controlling surgical bleeding and 
innovatively controlling surgical bleeding and 
innovatively controlling surgical bleeding and
innovatively controlling surgical bleeding and 
infection globally. Our goal and commitment is 
infection globally. Our goal and commitment is 
infection globally. Our goal and commitment is
infection globally. Our goal and commitment is 
to now create the next frontier of surgery. That’s
to now create the next frontier of surgery. That’s
to now create the next frontier of surgery. That’s
to now create the next frontier of surgery. That’s
why I’m excited that we entered into a definitive
why I’m excited that we entered into a definitive
why I’m excited that we entered into a definitive
why I’m excited that we entered into a definitive
agreement to acquire Auris Health, Inc. Auris 
agreement to acquire Auris Health, Inc. Auris 
agreement to acquire Auris Health, Inc. Auris
agreement to acquire Auris Health, Inc. Auris 
Health is a developer of robotic technologies
Health is a developer of robotic technologies
Health is a developer of robotic technologies
Health is a developer of robotic technologies
that currently focuses on lung cancer. This
that currently focuses on lung cancer. This
that currently focuses on lung cancer. This
that currently focuses on lung cancer. This
acquisition will accelerate our entry into digitally
acquisition will accelerate our entry into digitally
acquisition will accelerate our entry into digitally
acquisition will accelerate our entry into digitally
enabled robotics procedures with the potential
enabled robotics procedures with the potential
enabled robotics procedures with the potential
enabled robotics procedures with the potential
for growth and expansion into other interventional 
for growth and expansion into other interventional 
for growth and expansion into other interventional
for growth and expansion into other interventional 
applications. In this new era of healthcare, we
applications. In this new era of healthcare, we
applications. In this new era of healthcare, we
applications. In this new era of healthcare, we
are aiming to simplify surgery, drive efficiency,
are aiming to simplify surgery, drive efficiency,
are aiming to simplify surgery, drive efficiency,
are aiming to simplify surgery, drive efficiency,
reduce complications, improve outcomes for 
reduce complications, improve outcomes for 
reduce complications, improve outcomes for
reduce complications, improve outcomes for 
patients and make surgery even safer. This 
patients and make surgery even safer. This 
patients and make surgery even safer. This
patients and make surgery even safer. This 
continues our surgical leadership that has been 
continues our surgical leadership that has been
continues our surgical leadership that has been 
continues our surgical leadership that has been 
in motion since the beginning of our Company.
in motion since the beginning of our Company.
in motion since the beginning of our Company.
in motion since the beginning of our Company.
Looking ahead, I am also very excited about our
Looking ahead, I am also very excited about our
Looking ahead, I am also very excited about our
Looking ahead, I am also very excited about our
collaboration with Apple, Inc. that we announced 
collaboration with Apple, Inc. that we announced
collaboration with Apple, Inc. that we announced 
collaboration with Apple, Inc. that we announced 
early in 2019. Together, we will be conducting a
early in 2019. Together, we will be conducting a
early in 2019. Together, we will be conducting a
early in 2019. Together, we will be conducting a
research study that analyzes whether a new heart 
research study that analyzes whether a new heart 
research study that analyzes whether a new heart
research study that analyzes whether a new heart 
health program using an app from the Johnson 
health program using an app from the Johnson 
health program using an app from the Johnson
health program using an app from the Johnson 
& Johnson Family of Companies, in combination 
& Johnson Family of Companies, in combination
& Johnson Family of Companies, in combination 
& Johnson Family of Companies, in combination 
i
with Apple Watch’s irregular rhythm notifications 
with Apple Watch’s irregular rhythm notifications
with Apple Watch’s irregular rhythm notifications 
and Electro Cardiogram (ECG) app, can 
and Electro Cardiogram (ECG) app, can 
and Electro Cardiogram (ECG) app, can
and Electro Cardiogram (ECG) app, can 
accelerate atrial fibrillation (AFib) diagnosis, and
accelerate atrial fibrillation (AFib) diagnosis, and
accelerate atrial fibrillation (AFib) diagnosis, and
accelerate atrial fibrillation (AFib) diagnosis, and
improve health outcomes including the prevention 
improve health outcomes including the prevention
improve health outcomes including the prevention 
improve health outcomes including the prevention 
of stroke for the 33 million people worldwide 
of stroke for the 33 million people worldwide 
of stroke for the 33 million people worldwide
of stroke for the 33 million people worldwide 
living with AFib. This is a condition that can
living with AFib. This is a condition that can
living with AFib. This is a condition that can
living with AFib. This is a condition that can
lead to stroke and other potentially devastating
lead to stroke and other potentially devastating
lead to stroke and other potentially devastating
lead to stroke and other potentially devastating
h h
i h
ifi
h’
l
l
i
(cid:68)(cid:79)(cid:82)(cid:81)(cid:72)(cid:15) (cid:36)(cid:41)(cid:76)(cid:69)(cid:36)(cid:41)(cid:76)(cid:69)(cid:36)(cid:41)(cid:76)(cid:69) (cid:76)(cid:86)(cid:76)(cid:86)(cid:76)(cid:86)
(cid:73)(cid:68)(cid:70)(cid:87)(cid:15) (cid:76)(cid:76)(cid:81)(cid:76)(cid:81) (cid:87)(cid:75)(cid:72)(cid:87)(cid:75)(cid:72)(cid:87)(cid:75)(cid:72) (cid:56)(cid:17)(cid:54)(cid:17)(cid:56)(cid:17)(cid:54)(cid:17)(cid:56)(cid:17)(cid:54)(cid:17) (cid:68)(cid:79)(cid:82)(cid:81)(cid:72)(cid:15)
(cid:70)(cid:82)(cid:80)(cid:83)(cid:79)(cid:76)(cid:70)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:86)(cid:17) (cid:44)(cid:81)(cid:44)(cid:81)(cid:44)(cid:81) (cid:73)(cid:68)(cid:70)(cid:87)(cid:15)
(cid:70)(cid:82)(cid:80)(cid:83)(cid:79)(cid:76)(cid:70)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:86)(cid:17)
(cid:70)(cid:82)(cid:80)(cid:83)(cid:79)(cid:76)(cid:70)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:86)(cid:17) (cid:44)(cid:81) (cid:73)(cid:68)(cid:70)(cid:87)(cid:15) (cid:76)(cid:81) (cid:87)(cid:75)(cid:72) (cid:56)(cid:17)(cid:54)(cid:17) (cid:68)(cid:79)(cid:82)(cid:81)(cid:72)(cid:15) (cid:36)(cid:41)(cid:76)(cid:69) (cid:76)(cid:86)
(cid:68)(cid:79)(cid:82)(cid:81)(cid:72)(cid:15)
(cid:73)(cid:68)(cid:70)(cid:87)(cid:15)
(cid:70)(cid:82)(cid:80)(cid:83)(cid:79)(cid:76)(cid:70)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:86)(cid:17)
responsible for approximately 130,000 deaths
responsible for approximately 130,000 deaths
responsible for approximately 130,000 deaths
responsible for approximately 130,000 deaths
and 750,000 hospitalizations every year.
and 750,000 hospitalizations every year.
and 750,000 hospitalizations every year.
and 750,000 hospitalizations every year.
We are very optimistic about the potential
We are very optimistic about the potential
We are very optimistic about the potential
We are very optimistic about the potential
of this wearable technology. And, based on 
of this wearable technology. And, based on 
of this wearable technology. And, based on
of this wearable technology. And, based on 
the insights generated through this research
the insights generated through this research
the insights generated through this research
the insights generated through this research
program, in the future we may also be able
program, in the future we may also be able
program, in the future we may also be able
program, in the future we may also be able
to develop new ways to detect other health 
to develop new ways to detect other health
to develop new ways to detect other health 
to develop new ways to detect other health 
conditions sooner. Early diagnosis not only
conditions sooner. Early diagnosis not only
conditions sooner. Early diagnosis not only
conditions sooner. Early diagnosis not only
has the potential to save lives, but it may also
has the potential to save lives, but it may also
has the potential to save lives, but it may also
has the potential to save lives, but it may also
lower costs across the healthcare system. 
lower costs across the healthcare system.
lower costs across the healthcare system. 
lower costs across the healthcare system. 
Innovation is our calling card to the world of
Innovation is our calling card to the world of
Innovation is our calling card to the world of
Innovation is our calling card to the world of
science and technology. We remain open to the 
science and technology. We remain open to the 
science and technology. We remain open to the
science and technology. We remain open to the 
best ideas, no matter where they come from, 
best ideas, no matter where they come from, 
best ideas, no matter where they come from,
best ideas, no matter where they come from, 
as we relentlessly pursue transformational
as we relentlessly pursue transformational
as we relentlessly pursue transformational
as we relentlessly pursue transformational
innovation to benefit human health, internally
innovation to benefit human health, internally
innovation to benefit human health, internally
innovation to benefit human health, internally
and throughout our innovation ecosystem, 
and throughout our innovation ecosystem, 
and throughout our innovation ecosystem,
and throughout our innovation ecosystem, 
across our Innovation Centers, JLABs,
across our Innovation Centers, JLABs,
across our Innovation Centers, JLABs,
across our Innovation Centers, JLABs,
JJDC and many strategic partnerships. 
JJDC and many strategic partnerships.
JJDC and many strategic partnerships. 
JJDC and many strategic partnerships. 
Driving Long-term Shareholder Value
Driving Long-term Shareholder Value
Driving Long-term Shareholder Value
Driving Long-term Shareholder Value
Our free cash flow* for 2018 improved to $18.5
Our free cash flow* for 2018 improved to $18.5
Our free cash flow* for 2018 improved to $18.5
Our free cash flow* for 2018 improved to $18.5
billion, and employing our proven capital
billion, and employing our proven capital
billion, and employing our proven capital
billion, and employing our proven capital
allocation strategy, we are able to effectively 
allocation strategy, we are able to effectively 
allocation strategy, we are able to effectively
allocation strategy, we are able to effectively 
invest in our business and innovation to drive 
invest in our business and innovation to drive 
invest in our business and innovation to drive
invest in our business and innovation to drive
growth for long-term value, while also returning 
growth for long-term value, while also returning
growth for long-term value, while also returning 
growth for long-term value, while also returning 
value to shareholders. Our capital allocation
value to shareholders. Our capital allocation
value to shareholders. Our capital allocation
value to shareholders. Our capital allocation
strategy includes four key priorities: 
strategy includes four key priorities:
strategy includes four key priorities: 
strategy includes four key priorities: 
(cid:76)(cid:81)(cid:87)(cid:72)(cid:85)(cid:81)(cid:68)(cid:79) (cid:74)(cid:85)(cid:82)(cid:90)(cid:87)(cid:75)
(cid:83)(cid:85)(cid:76)(cid:82)(cid:85)(cid:76)(cid:87)(cid:92) (cid:76)(cid:86)(cid:76)(cid:86)(cid:76)(cid:86) (cid:87)(cid:82)(cid:87)(cid:82)(cid:87)(cid:82) (cid:73)(cid:88)(cid:81)(cid:71)(cid:73)(cid:88)(cid:81)(cid:71)(cid:73)(cid:88)(cid:81)(cid:71) (cid:82)(cid:88)(cid:85)(cid:82)(cid:88)(cid:85)(cid:82)(cid:88)(cid:85) (cid:76)(cid:81)(cid:87)(cid:72)(cid:85)(cid:81)(cid:68)(cid:79)
(cid:373) (cid:50)(cid:88)(cid:85) (cid:612)(cid:85)(cid:86)(cid:87)(cid:612)(cid:85)(cid:86)(cid:87)(cid:612)(cid:85)(cid:86)(cid:87) (cid:83)(cid:85)(cid:76)(cid:82)(cid:85)(cid:76)(cid:87)(cid:92)
(cid:373)(cid:3) (cid:50)(cid:88)(cid:85)
(cid:74)(cid:85)(cid:82)(cid:90)(cid:87)(cid:75)
(cid:373)(cid:3) (cid:50)(cid:88)(cid:85) (cid:612)(cid:85)(cid:86)(cid:87) (cid:83)(cid:85)(cid:76)(cid:82)(cid:85)(cid:76)(cid:87)(cid:92) (cid:76)(cid:86) (cid:87)(cid:82) (cid:73)(cid:88)(cid:81)(cid:71) (cid:82)(cid:88)(cid:85) (cid:76)(cid:81)(cid:87)(cid:72)(cid:85)(cid:81)(cid:68)(cid:79) (cid:74)(cid:85)(cid:82)(cid:90)(cid:87)(cid:75)
(cid:74)(cid:85)(cid:82)(cid:90)(cid:87)(cid:75)
(cid:76)(cid:81)(cid:87)(cid:72)(cid:85)(cid:81)(cid:68)(cid:79)
(cid:83)(cid:85)(cid:76)(cid:82)(cid:85)(cid:76)(cid:87)(cid:92)
(cid:373) (cid:50)(cid:88)(cid:85)
(cid:54)(cid:48)(cid:9)(cid:36) (cid:11)(cid:86)(cid:72)(cid:79)(cid:79)(cid:76)(cid:81)(cid:74)(cid:15)
(cid:82)(cid:83)(cid:83)(cid:82)(cid:85)(cid:87)(cid:88)(cid:81)(cid:76)(cid:87)(cid:76)(cid:72)(cid:86) (cid:89)(cid:76)(cid:68)(cid:89)(cid:76)(cid:68)(cid:89)(cid:76)(cid:68) (cid:53)(cid:9)(cid:39)(cid:53)(cid:9)(cid:39)(cid:53)(cid:9)(cid:39) (cid:68)(cid:81)(cid:71)(cid:68)(cid:81)(cid:71)(cid:68)(cid:81)(cid:71) (cid:54)(cid:48)(cid:9)(cid:36)
(cid:82)(cid:83)(cid:83)(cid:82)(cid:85)(cid:87)(cid:88)(cid:81)(cid:76)(cid:87)(cid:76)(cid:72)(cid:86)
(cid:82)(cid:83)(cid:83)(cid:82)(cid:85)(cid:87)(cid:88)(cid:81)(cid:76)(cid:87)(cid:76)(cid:72)(cid:86) (cid:89)(cid:76)(cid:68) (cid:53)(cid:9)(cid:39) (cid:68)(cid:81)(cid:71) (cid:54)(cid:48)(cid:9)(cid:36) (cid:11)(cid:86)(cid:72)(cid:79)(cid:79)(cid:76)(cid:81)(cid:74)(cid:15)
(cid:11)(cid:86)(cid:72)(cid:79)(cid:79)(cid:76)(cid:81)(cid:74)(cid:15)
(cid:11)(cid:86)(cid:72)(cid:79)(cid:79)(cid:76)(cid:81)(cid:74)(cid:15)
(cid:54)(cid:48)(cid:9)(cid:36)
(cid:82)(cid:83)(cid:83)(cid:82)(cid:85)(cid:87)(cid:88)(cid:81)(cid:76)(cid:87)(cid:76)(cid:72)(cid:86)
marketing and administrative) initiatives.
marketing and administrative) initiatives.
marketing and administrative) initiatives.
marketing and administrative) initiatives.
(cid:71)(cid:72)(cid:79)(cid:76)(cid:89)(cid:72)(cid:85) (cid:68)(cid:68)(cid:68) (cid:70)(cid:82)(cid:80)(cid:83)(cid:72)(cid:87)(cid:76)(cid:87)(cid:76)(cid:89)(cid:72)
(cid:83)(cid:85)(cid:76)(cid:82)(cid:85)(cid:76)(cid:87)(cid:92) (cid:76)(cid:86)(cid:76)(cid:86)(cid:76)(cid:86) (cid:87)(cid:82)(cid:87)(cid:82)(cid:87)(cid:82) (cid:71)(cid:72)(cid:79)(cid:76)(cid:89)(cid:72)(cid:85)
(cid:373) (cid:55)(cid:75)(cid:72) (cid:81)(cid:72)(cid:91)(cid:87)(cid:81)(cid:72)(cid:91)(cid:87)(cid:81)(cid:72)(cid:91)(cid:87) (cid:83)(cid:85)(cid:76)(cid:82)(cid:85)(cid:76)(cid:87)(cid:92)
(cid:373)(cid:3) (cid:55)(cid:75)(cid:72)
(cid:70)(cid:82)(cid:80)(cid:83)(cid:72)(cid:87)(cid:76)(cid:87)(cid:76)(cid:89)(cid:72)
(cid:373)(cid:3) (cid:55)(cid:75)(cid:72) (cid:81)(cid:72)(cid:91)(cid:87) (cid:83)(cid:85)(cid:76)(cid:82)(cid:85)(cid:76)(cid:87)(cid:92) (cid:76)(cid:86) (cid:87)(cid:82) (cid:71)(cid:72)(cid:79)(cid:76)(cid:89)(cid:72)(cid:85) (cid:68) (cid:70)(cid:82)(cid:80)(cid:83)(cid:72)(cid:87)(cid:76)(cid:87)(cid:76)(cid:89)(cid:72)
(cid:70)(cid:82)(cid:80)(cid:83)(cid:72)(cid:87)(cid:76)(cid:87)(cid:76)(cid:89)(cid:72)
(cid:71)(cid:72)(cid:79)(cid:76)(cid:89)(cid:72)(cid:85)
(cid:83)(cid:85)(cid:76)(cid:82)(cid:85)(cid:76)(cid:87)(cid:92)
(cid:373) (cid:55)(cid:75)(cid:72)
dividend to our shareholders, and in 2018
dividend to our shareholders, and in 2018
dividend to our shareholders, and in 2018
dividend to our shareholders, and in 2018
we paid $9.5 billion in dividends. We are 
we paid $9.5 billion in dividends. We are 
we paid $9.5 billion in dividends. We are
we paid $9.5 billion in dividends. We are 
very proud that our dividend has increased 
very proud that our dividend has increased 
very proud that our dividend has increased
very proud that our dividend has increased 
for the last 56 consecutive years. 
for the last 56 consecutive years.
for the last 56 consecutive years. 
for the last 56 consecutive years. 
(cid:74)(cid:82)(cid:68)(cid:79)(cid:86)(cid:15) (cid:90)(cid:72)(cid:90)(cid:72)(cid:90)(cid:72)
(cid:71)(cid:76)(cid:89)(cid:76)(cid:71)(cid:72)(cid:81)(cid:71) (cid:74)(cid:82)(cid:68)(cid:79)(cid:86)(cid:15)
(cid:373) (cid:50)(cid:81)(cid:70)(cid:72) (cid:90)(cid:72)(cid:366)(cid:89)(cid:72)(cid:90)(cid:72)(cid:366)(cid:89)(cid:72)(cid:90)(cid:72)(cid:366)(cid:89)(cid:72) (cid:80)(cid:72)(cid:87)(cid:80)(cid:72)(cid:87)(cid:80)(cid:72)(cid:87) (cid:82)(cid:88)(cid:85)(cid:82)(cid:88)(cid:85)(cid:82)(cid:88)(cid:85) (cid:71)(cid:76)(cid:89)(cid:76)(cid:71)(cid:72)(cid:81)(cid:71)
(cid:373)(cid:3) (cid:50)(cid:81)(cid:70)(cid:72)
(cid:373)(cid:3) (cid:50)(cid:81)(cid:70)(cid:72) (cid:90)(cid:72)(cid:366)(cid:89)(cid:72) (cid:80)(cid:72)(cid:87) (cid:82)(cid:88)(cid:85) (cid:71)(cid:76)(cid:89)(cid:76)(cid:71)(cid:72)(cid:81)(cid:71) (cid:74)(cid:82)(cid:68)(cid:79)(cid:86)(cid:15) (cid:90)(cid:72)
(cid:74)(cid:82)(cid:68)(cid:79)(cid:86)(cid:15)
(cid:71)(cid:76)(cid:89)(cid:76)(cid:71)(cid:72)(cid:81)(cid:71)
(cid:373) (cid:50)(cid:81)(cid:70)(cid:72)
target mergers, acquisitions and licensing 
target mergers, acquisitions and licensing 
target mergers, acquisitions and licensing
target mergers, acquisitions and licensing 
agreements that we believe will add 
agreements that we believe will add 
agreements that we believe will add
agreements that we believe will add 
significant long-term value creation for our 
significant long-term value creation for our
significant long-term value creation for our 
significant long-term value creation for our 
shareholders and all other stakeholders.
shareholders and all other stakeholders.
shareholders and all other stakeholders.
shareholders and all other stakeholders.
(cid:83)(cid:85)(cid:88)(cid:71)(cid:72)(cid:81)(cid:87) (cid:90)(cid:68)(cid:92)(cid:86)(cid:90)(cid:68)(cid:92)(cid:86)(cid:90)(cid:68)(cid:92)(cid:86)
(cid:82)(cid:87)(cid:75)(cid:72)(cid:85) (cid:83)(cid:85)(cid:88)(cid:71)(cid:72)(cid:81)(cid:87)
(cid:70)(cid:82)(cid:81)(cid:86)(cid:76)(cid:71)(cid:72)(cid:85) (cid:82)(cid:87)(cid:75)(cid:72)(cid:85)
(cid:612)(cid:81)(cid:68)(cid:79)(cid:79)(cid:92)(cid:15) (cid:90)(cid:72)(cid:90)(cid:72)(cid:90)(cid:72) (cid:70)(cid:82)(cid:81)(cid:86)(cid:76)(cid:71)(cid:72)(cid:85)
(cid:373) (cid:36)(cid:81)(cid:71) (cid:612)(cid:81)(cid:68)(cid:79)(cid:79)(cid:92)(cid:15)
(cid:373)(cid:3) (cid:36)(cid:81)(cid:71)
(cid:373)(cid:3) (cid:36)(cid:81)(cid:71) (cid:612)(cid:81)(cid:68)(cid:79)(cid:79)(cid:92)(cid:15) (cid:90)(cid:72) (cid:70)(cid:82)(cid:81)(cid:86)(cid:76)(cid:71)(cid:72)(cid:85) (cid:82)(cid:87)(cid:75)(cid:72)(cid:85) (cid:83)(cid:85)(cid:88)(cid:71)(cid:72)(cid:81)(cid:87) (cid:90)(cid:68)(cid:92)(cid:86)
(cid:83)(cid:85)(cid:88)(cid:71)(cid:72)(cid:81)(cid:87)
(cid:82)(cid:87)(cid:75)(cid:72)(cid:85)
(cid:70)(cid:82)(cid:81)(cid:86)(cid:76)(cid:71)(cid:72)(cid:85)
(cid:612)(cid:81)(cid:68)(cid:79)(cid:79)(cid:92)(cid:15)
(cid:373) (cid:36)(cid:81)(cid:71)
to return value to shareholders, such as share
to return value to shareholders, such as share
to return value to shareholders, such as share
to return value to shareholders, such as share
repurchase programs; and we are currently 
repurchase programs; and we are currently
repurchase programs; and we are currently 
repurchase programs; and we are currently 
executing against a $5 billion share repurchase 
executing against a $5 billion share repurchase 
executing against a $5 billion share repurchase
executing against a $5 billion share repurchase 
that we announced last December.
that we announced last December.
that we announced last December.
that we announced last December.
Given our financial strength, we can pursue all
Given our financial strength, we can pursue all
Given our financial strength, we can pursue all
Given our financial strength, we can pursue all
of these priorities simultaneously, as we did in
of these priorities simultaneously, as we did in
of these priorities simultaneously, as we did in
of these priorities simultaneously, as we did in
2018. Throughout Johnson & Johnson’s history,
2018. Throughout Johnson & Johnson’s history,
2018. Throughout Johnson & Johnson’s history,
2018. Throughout Johnson & Johnson’s history,
we have maintained a strong, consistent and
we have maintained a strong, consistent and
we have maintained a strong, consistent and
we have maintained a strong, consistent and
sustainable business. This is illustrated by:
sustainable business. This is illustrated by:
sustainable business. This is illustrated by:
sustainable business. This is illustrated by:
(cid:92)(cid:72)(cid:68)(cid:85)(cid:86) (cid:82)(cid:73)(cid:82)(cid:73)(cid:82)(cid:73) (cid:68)(cid:71)(cid:77)(cid:88)(cid:86)(cid:87)(cid:72)(cid:71)
(cid:70)(cid:82)(cid:81)(cid:86)(cid:72)(cid:70)(cid:88)(cid:87)(cid:76)(cid:89)(cid:72) (cid:92)(cid:72)(cid:68)(cid:85)(cid:86)
(cid:373)(cid:3) (cid:22)(cid:24)(cid:373) (cid:22)(cid:24)(cid:373) (cid:22)(cid:24) (cid:70)(cid:82)(cid:81)(cid:86)(cid:72)(cid:70)(cid:88)(cid:87)(cid:76)(cid:89)(cid:72)
(cid:373)(cid:3) (cid:22)(cid:24) (cid:70)(cid:82)(cid:81)(cid:86)(cid:72)(cid:70)(cid:88)(cid:87)(cid:76)(cid:89)(cid:72) (cid:92)(cid:72)(cid:68)(cid:85)(cid:86) (cid:82)(cid:73) (cid:68)(cid:71)(cid:77)(cid:88)(cid:86)(cid:87)(cid:72)(cid:71)
(cid:68)(cid:71)(cid:77)(cid:88)(cid:86)(cid:87)(cid:72)(cid:71)
(cid:68)(cid:71)(cid:77)(cid:88)(cid:86)(cid:87)(cid:72)(cid:71)
(cid:92)(cid:72)(cid:68)(cid:85)(cid:86)
(cid:70)(cid:82)(cid:81)(cid:86)(cid:72)(cid:70)(cid:88)(cid:87)(cid:76)(cid:89)(cid:72)
operational earnings growth*
operational earnings growth*
operational earnings growth*
operational earnings growth*
(cid:70)(cid:82)(cid:80)(cid:83)(cid:68)(cid:81)(cid:76)(cid:72)(cid:86) (cid:87)(cid:75)(cid:68)(cid:87)
(cid:373)(cid:3) (cid:37)(cid:72)(cid:76)(cid:81)(cid:74) (cid:82)(cid:81)(cid:72)(cid:82)(cid:81)(cid:72)(cid:82)(cid:81)(cid:72) (cid:82)(cid:73)(cid:82)(cid:73)(cid:82)(cid:73) (cid:82)(cid:81)(cid:79)(cid:92)(cid:82)(cid:81)(cid:79)(cid:92)(cid:82)(cid:81)(cid:79)(cid:92) (cid:87)(cid:90)(cid:82)(cid:87)(cid:90)(cid:82)(cid:87)(cid:90)(cid:82) (cid:70)(cid:82)(cid:80)(cid:83)(cid:68)(cid:81)(cid:76)(cid:72)(cid:86)
(cid:373)(cid:3) (cid:37)(cid:72)(cid:76)(cid:81)(cid:74)
(cid:87)(cid:75)(cid:68)(cid:87)
(cid:373)(cid:3) (cid:37)(cid:72)(cid:76)(cid:81)(cid:74) (cid:82)(cid:81)(cid:72) (cid:82)(cid:73) (cid:82)(cid:81)(cid:79)(cid:92) (cid:87)(cid:90)(cid:82) (cid:70)(cid:82)(cid:80)(cid:83)(cid:68)(cid:81)(cid:76)(cid:72)(cid:86) (cid:87)(cid:75)(cid:68)(cid:87)
(cid:87)(cid:75)(cid:68)(cid:87)
(cid:70)(cid:82)(cid:80)(cid:83)(cid:68)(cid:81)(cid:76)(cid:72)(cid:86)
(cid:373)(cid:3) (cid:37)(cid:72)(cid:76)(cid:81)(cid:74)
hold a Triple A credit rating; and 
hold a Triple A credit rating; and
hold a Triple A credit rating; and 
hold a Triple A credit rating; and 
(cid:54)(cid:87)(cid:68)(cid:81)(cid:71)(cid:68)(cid:85)(cid:71) (cid:9)(cid:9)(cid:9) (cid:51)(cid:82)(cid:82)(cid:85)(cid:366)(cid:86)
(cid:68)(cid:80)(cid:82)(cid:81)(cid:74) (cid:54)(cid:87)(cid:68)(cid:81)(cid:71)(cid:68)(cid:85)(cid:71)
(cid:86)(cid:87)(cid:68)(cid:81)(cid:71)(cid:76)(cid:81)(cid:74) (cid:68)(cid:80)(cid:82)(cid:81)(cid:74)
(cid:373) (cid:50)(cid:88)(cid:85) (cid:86)(cid:87)(cid:68)(cid:81)(cid:71)(cid:76)(cid:81)(cid:74)
(cid:373)(cid:3) (cid:50)(cid:88)(cid:85)
(cid:51)(cid:82)(cid:82)(cid:85)(cid:366)(cid:86)
(cid:373)(cid:3) (cid:50)(cid:88)(cid:85) (cid:86)(cid:87)(cid:68)(cid:81)(cid:71)(cid:76)(cid:81)(cid:74) (cid:68)(cid:80)(cid:82)(cid:81)(cid:74) (cid:54)(cid:87)(cid:68)(cid:81)(cid:71)(cid:68)(cid:85)(cid:71) (cid:9) (cid:51)(cid:82)(cid:82)(cid:85)(cid:366)(cid:86)
(cid:51)(cid:82)(cid:82)(cid:85)(cid:366)(cid:86)
(cid:54)(cid:87)(cid:68)(cid:81)(cid:71)(cid:68)(cid:85)(cid:71)
(cid:68)(cid:80)(cid:82)(cid:81)(cid:74)
(cid:86)(cid:87)(cid:68)(cid:81)(cid:71)(cid:76)(cid:81)(cid:74)
(cid:373) (cid:50)(cid:88)(cid:85)
Top 10 Market Cap companies.
Top 10 Market Cap companies.
Top 10 Market Cap companies.
Top 10 Market Cap companies.
The Strategic AAAdvantage of Our Broad Base
The Strategic
The Strategic Advantage of Our Broad Base
dvantage of Our Broad Base
dvantage of Our Broad Base
The Strategic
Positioned across three vital aspects of 
Positioned across three vital aspects of 
Positioned across three vital aspects of
Positioned across three vital aspects of 
healthcare—Pharmaceutical, Consumer and 
healthcare—Pharmaceutical, Consumer and
healthcare—Pharmaceutical, Consumer and 
healthcare—Pharmaceutical, Consumer and 
Medical Devices—we have unique insight into
Medical Devices—we have unique insight into
Medical Devices—we have unique insight into
Medical Devices—we have unique insight into
challenges and opportunities whenever and
challenges and opportunities whenever and
challenges and opportunities whenever and
challenges and opportunities whenever and
wherever they emerge. We are structured to
wherever they emerge. We are structured to
wherever they emerge. We are structured to
wherever they emerge. We are structured to
meet the current and future needs of patients 
meet the current and future needs of patients
meet the current and future needs of patients 
meet the current and future needs of patients 
and consumers globally, and to address the 
and consumers globally, and to address the 
and consumers globally, and to address the
and consumers globally, and to address the 
challenges and opportunities that the world
challenges and opportunities that the world
challenges and opportunities that the world
challenges and opportunities that the world
of healthcare presents. We remain focused on 
of healthcare presents. We remain focused on 
of healthcare presents. We remain focused on
of healthcare presents. We remain focused on 
leveraging our broad-based capabilities to 
leveraging our broad-based capabilities to
leveraging our broad-based capabilities to 
leveraging our broad-based capabilities to 
(cid:38) (cid:43) (cid:36) (cid:44) (cid:53) (cid:48) (cid:36) (cid:49) (cid:366) (cid:54) (cid:3) (cid:47) (cid:40) (cid:55) (cid:55) (cid:40) (cid:53) (cid:3) (cid:373) (cid:3) (cid:44) (cid:44) (cid:44)

--- Page 6 ---
continue to drive the next generation of growth
continue to drive the next generation of growth
continue to drive the next generation of growth
continue to drive the next generation of growth
across our entire portfolio, both in markets 
across our entire portfolio, both in markets
across our entire portfolio, both in markets 
across our entire portfolio, both in markets 
where we have greater opportunity to compete,
where we have greater opportunity to compete,
where we have greater opportunity to compete,
where we have greater opportunity to compete,
as well as in the markets where we lead, which 
as well as in the markets where we lead, which 
as well as in the markets where we lead, which
as well as in the markets where we lead, which 
include our 26 platforms that each delivered
include our 26 platforms that each delivered
include our 26 platforms that each delivered
include our 26 platforms that each delivered
a billion dollars or more in sales last year.
a billion dollars or more in sales last year.
a billion dollars or more in sales last year.
a billion dollars or more in sales last year.
Our broad base is not just our heritage, it
Our broad base is not just our heritage, it
Our broad base is not just our heritage, it
Our broad base is not just our heritage, it
is a strategic choice, grounded and proven 
is a strategic choice, grounded and proven 
is a strategic choice, grounded and proven
is a strategic choice, grounded and proven 
in long-term performance and our broad 
in long-term performance and our broad
in long-term performance and our broad 
in long-term performance and our broad 
and deep understanding of the industry’s
and deep understanding of the industry’s
and deep understanding of the industry’s
and deep understanding of the industry’s
present and future. We clearly recognize the
present and future. We clearly recognize the
present and future. We clearly recognize the
present and future. We clearly recognize the
important role we play in leading responsibly
important role we play in leading responsibly
important role we play in leading responsibly
important role we play in leading responsibly
and representing our industry with integrity.
and representing our industry with integrity.
and representing our industry with integrity.
and representing our industry with integrity.
Our “Health for Humanity Report” underscores
Our “Health for Humanity Report” underscores
Our “Health for Humanity Report” underscores
Our “Health for Humanity Report” underscores
our commitment to help ensure that each new
our commitment to help ensure that each new
our commitment to help ensure that each new
our commitment to help ensure that each new
generation is healthier than the last. We believe
generation is healthier than the last. We believe
generation is healthier than the last. We believe
generation is healthier than the last. We believe
our broad base helps us better understand and 
our broad base helps us better understand and 
our broad base helps us better understand and
our broad base helps us better understand and 
positively impact human health at every age and 
positively impact human health at every age and 
positively impact human health at every age and
positively impact human health at every age and 
at every stage. In 2018 we were recognized as one 
at every stage. In 2018 we were recognized as one 
at every stage. In 2018 we were recognized as one
at every stage. In 2018 we were recognized as one 
of the top ten corporations for our environmental, 
of the top ten corporations for our environmental,
of the top ten corporations for our environmental, 
of the top ten corporations for our environmental, 
social and governance performance by 
social and governance performance by 
social and governance performance by
social and governance performance by 
Corporate Responsibility Magazine. 
Corporate Responsibility Magazine.
Corporate Responsibility Magazine. 
Corporate Responsibility Magazine. 
Our broad base is not just our heritage, 
it is a strategic choice, grounded and 
proven in long-term performance and 
our broad and deep understanding of 
the industry’s present and future. 
Business Performance and 2019 Outlook 
Business Performance and 2019 Outlook
Business Performance and 2019 Outlook 
Business Performance and 2019 Outlook
i h
i d
Pharmaceutical
Pharmaceutical
Pharmaceutical
Pharmaceutical
bli h d
With an industry-leading pipeline and established 
With an industry-leading pipeline and established
With an industry-leading pipeline and established 
commercial excellence, our Pharmaceutical 
commercial excellence, our Pharmaceutical 
commercial excellence, our Pharmaceutical
commercial excellence, our Pharmaceutical 
d
b i
business has delivered outstanding performance
business has delivered outstanding performance 
business has delivered outstanding performance 
l di
d li
di
d
h
li
f
i
(cid:92)(cid:72)(cid:68)(cid:85)(cid:86)(cid:17) (cid:54)(cid:88)(cid:70)(cid:70)(cid:72)(cid:86)(cid:86)(cid:73)(cid:88)(cid:79)
(cid:86)(cid:72)(cid:89)(cid:72)(cid:85)(cid:68)(cid:79) (cid:92)(cid:72)(cid:68)(cid:85)(cid:86)
(cid:73)(cid:82)(cid:85)(cid:73)(cid:82)(cid:85)(cid:73)(cid:82)(cid:85) (cid:87)(cid:75)(cid:72)(cid:87)(cid:75)(cid:72)(cid:87)(cid:75)(cid:72) (cid:83)(cid:68)(cid:86)(cid:87)(cid:83)(cid:68)(cid:86)(cid:87)(cid:83)(cid:68)(cid:86)(cid:87) (cid:86)(cid:72)(cid:89)(cid:72)(cid:85)(cid:68)(cid:79)
(cid:73)(cid:82)(cid:85) (cid:87)(cid:75)(cid:72) (cid:83)(cid:68)(cid:86)(cid:87) (cid:86)(cid:72)(cid:89)(cid:72)(cid:85)(cid:68)(cid:79) (cid:92)(cid:72)(cid:68)(cid:85)(cid:86)(cid:17) (cid:54)(cid:88)(cid:70)(cid:70)(cid:72)(cid:86)(cid:86)(cid:73)(cid:88)(cid:79)
(cid:54)(cid:88)(cid:70)(cid:70)(cid:72)(cid:86)(cid:86)(cid:73)(cid:88)(cid:79)
(cid:54)(cid:88)(cid:70)(cid:70)(cid:72)(cid:86)(cid:86)(cid:73)(cid:88)(cid:79)
(cid:92)(cid:72)(cid:68)(cid:85)(cid:86)(cid:17)
(cid:86)(cid:72)(cid:89)(cid:72)(cid:85)(cid:68)(cid:79)
launches and strong growth in several of
launches and strong growth in several of
launches and strong growth in several of
launches and strong growth in several of
our blockbuster medicines created 11.8%
our blockbuster medicines created 11.8%
our blockbuster medicines created 11.8%
our blockbuster medicines created 11.8%
l
operational growth*, and our Pharmaceutical
operational growth*, and our Pharmaceutical
operational growth*, and our Pharmaceutical
business continues to be an industry leader in 
business continues to be an industry leader in 
business continues to be an industry leader in
business continues to be an industry leader in 
all performance measures, including R&D.
all performance measures, including R&D.
all performance measures, including R&D.
all performance measures, including R&D.
d
h
h
l
i
i
i
h
g g
d lib
y p
l
As we look toward 2019 and beyond, we remain
As we look toward 2019 and beyond, we remain
As we look toward 2019 and beyond, we remain
As we look toward 2019 and beyond, we remain
focused on bringing innovative solutions to 
focused on bringing innovative solutions to
focused on bringing innovative solutions to 
patients and healthcare providers globally,
patients and healthcare providers globally,
patients and healthcare providers globally,
patients and healthcare providers globally,
while driving strong growth and continuing
while driving strong growth and continuing
while driving strong growth and continuing
while driving strong growth and continuing
to advance our pipeline. Patent pressure is a 
to advance our pipeline. Patent pressure is a
to advance our pipeline. Patent pressure is a 
to advance our pipeline. Patent pressure is a 
feature of today’s pharmaceutical industry, and
feature of today’s pharmaceutical industry, and
feature of today’s pharmaceutical industry, and
d
we have deliberately and actively managed our
we have deliberately and actively managed our
we have deliberately and actively managed our
portfolio over the last few years to enable us 
portfolio over the last few years to enable us
portfolio over the last few years to enable us 
portfolio over the last few years to enable us 
to make the investments necessary to not only 
to make the investments necessary to not only
to make the investments necessary to not only 
y
i i
b
withstand this impact, but to grow at competitive
withstand this impact, but to grow at competitive
withstand this impact, but to grow at competitive
i
f
i
rates in 2019. We remain focused on developing
rates in 2019. We remain focused on developing
rates in 2019. We remain focused on developing
medicines and solutions that deliver great value 
medicines and solutions that deliver great value
medicines and solutions that deliver great value 
medicines and solutions that deliver great value 
to the patients and consumers who depend 
to the patients and consumers who depend
to the patients and consumers who depend 
on our products to make their lives better. Our
on our products to make their lives better. Our
on our products to make their lives better. Our
on our products to make their lives better. Our
goal and expectation for 2020 and beyond is
goal and expectation for 2020 and beyond is
goal and expectation for 2020 and beyond is
goal and expectation for 2020 and beyond is
sustained, long-term, above-market growth. 
sustained, long-term, above-market growth.
sustained, long-term, above-market growth. 
sustained, long-term, above-market growth. 
y
d
d hi
i h
p
p
d
d
y
l
l
i
i
k
i
We know that innovation drives our 
We know that innovation drives our
We know that innovation drives our
Pharmaceutical business’s success, and we
Pharmaceutical business’s success, and we
Pharmaceutical business’s success, and we
,
d i
h
i
Collaboration is fundamental to the work we do
Collaboration is fundamental to the work we do
Collaboration is fundamental to the work we do
Collaboration is fundamental to the work we do
every day and our presence in just about every
every day and our presence in just about every
every day and our presence in just about every
every day and our presence in just about every
area of healthcare. This level of engagement
area of healthcare. This level of engagement
area of healthcare. This level of engagement
area of healthcare. This level of engagement
allows us to maintain a continuous dialogue 
allows us to maintain a continuous dialogue
allows us to maintain a continuous dialogue 
allows us to maintain a continuous dialogue 
with healthcare professionals, business leaders, 
with healthcare professionals, business leaders,
with healthcare professionals, business leaders, 
with healthcare professionals, business leaders, 
academics, government officials, scientists, 
academics, government officials, scientists, 
academics, government officials, scientists,
academics, government officials, scientists, 
provider systems, customers, patients and
provider systems, customers, patients and
provider systems, customers, patients and
provider systems, customers, patients and
consumers. We remain committed to being a
consumers. We remain committed to being a
consumers. We remain committed to being a
consumers. We remain committed to being a
leader in the global healthcare space, to help drive
leader in the global healthcare space, to help drive
leader in the global healthcare space, to help drive
leader in the global healthcare space, to help drive
the change that people around the world want
the change that people around the world want
the change that people around the world want
the change that people around the world want
and need to see.
and need to see.
and need to see.
and need to see.
We see a vital and vibrant future for healthcare 
We see a vital and vibrant future for healthcare
We see a vital and vibrant future for healthcare
We see a vital and vibrant future for healthcare 
around the world that is being driven by the
around the world that is being driven by the
around the world that is being driven by the
around the world that is being driven by the
continuing expansion of the global middle 
continuing expansion of the global middle 
continuing expansion of the global middle
continuing expansion of the global middle 
class. It is the middle class that drives global 
class. It is the middle class that drives global
class. It is the middle class that drives global 
class. It is the middle class that drives global 
economic growth and with it, the demand for
economic growth and with it, the demand for
economic growth and with it, the demand for
economic growth and with it, the demand for
greater access to quality healthcare. I believe
greater access to quality healthcare. I believe
greater access to quality healthcare. I believe
greater access to quality healthcare. I believe
that no company on Earth is better positioned
that no company on Earth is better positioned
that no company on Earth is better positioned
that no company on Earth is better positioned
than Johnson & Johnson to capture this 
than Johnson & Johnson to capture this
than Johnson & Johnson to capture this 
than Johnson & Johnson to capture this 
opportunity and lead the healthcare industry. 
opportunity and lead the healthcare industry.
opportunity and lead the healthcare industry. 
opportunity and lead the healthcare industry. 
(cid:68)(cid:69)(cid:82)(cid:88)(cid:87) (cid:87)(cid:75)(cid:72)(cid:87)(cid:75)(cid:72)(cid:87)(cid:75)(cid:72) (cid:56)(cid:17)(cid:54)(cid:17)(cid:56)(cid:17)(cid:54)(cid:17)(cid:56)(cid:17)(cid:54)(cid:17) (cid:41) (cid:71)(cid:41)(cid:82)(cid:82)(cid:71)(cid:41)(cid:82)(cid:82)(cid:71) (cid:68)(cid:81)(cid:71)(cid:68)(cid:81)(cid:71)(cid:68)(cid:81)(cid:71) (cid:39)(cid:85)(cid:88)(cid:74)(cid:39)(cid:85)(cid:88)(cid:74)(cid:39)(cid:85)(cid:88)(cid:74)
(cid:72)(cid:91)(cid:70)(cid:76)(cid:87)(cid:72)(cid:71) (cid:68)(cid:69)(cid:82)(cid:88)(cid:87)
(cid:68)(cid:85)(cid:72)(cid:68)(cid:85)(cid:72)(cid:68)(cid:85)(cid:72) (cid:89)(cid:72)(cid:85)(cid:92)(cid:89)(cid:72)(cid:85)(cid:92)(cid:89)(cid:72)(cid:85)(cid:92) (cid:72)(cid:91)(cid:70)(cid:76)(cid:87)(cid:72)(cid:71)
(cid:68)(cid:69)(cid:82)(cid:88)(cid:87)
(cid:68)(cid:85)(cid:72) (cid:89)(cid:72)(cid:85)(cid:92) (cid:72)(cid:91)(cid:70)(cid:76)(cid:87)(cid:72)(cid:71) (cid:68)(cid:69)(cid:82)(cid:88)(cid:87) (cid:87)(cid:75)(cid:72) (cid:56)(cid:17)(cid:54)(cid:17) (cid:41)(cid:82)(cid:82)(cid:71) (cid:68)(cid:81)(cid:71)
(cid:72)(cid:91)(cid:70)(cid:76)(cid:87)(cid:72)(cid:71)
(cid:74)
(cid:11)(cid:41)(cid:39)(cid:36)(cid:12) (cid:68)(cid:83)(cid:83)(cid:85)(cid:82)(cid:89)(cid:68)(cid:79)
(cid:68)(cid:83)(cid:83)(cid:85)(cid:82)(cid:89)(cid:68)(cid:79) (cid:82)(cid:73)(cid:82)(cid:73)(cid:82)(cid:73) (cid:54)(cid:51)(cid:53)(cid:36)(cid:57)(cid:36)(cid:55)(cid:50)(cid:400)
(cid:36)(cid:71)(cid:80)(cid:76)(cid:81)(cid:76)(cid:86)(cid:87)(cid:85)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81) (cid:11)(cid:41)(cid:39)(cid:36)(cid:12)
(cid:36)(cid:71)(cid:80)(cid:76)(cid:81)(cid:76)(cid:86)(cid:87)(cid:85)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)
(cid:54)(cid:51)(cid:53)(cid:36)(cid:57)(cid:36)(cid:55)(cid:50)(cid:400)
(cid:36)(cid:71)(cid:80)(cid:76)(cid:81)(cid:76)(cid:86)(cid:87)(cid:85)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81) (cid:11)(cid:41)(cid:39)(cid:36)(cid:12) (cid:68)(cid:83)(cid:83)(cid:85)(cid:82)(cid:89)(cid:68)(cid:79) (cid:82)(cid:73) (cid:54)(cid:51)(cid:53)(cid:36)(cid:57)(cid:36)(cid:55)(cid:50)(cid:400)
(cid:54)(cid:51)(cid:53)(cid:36)(cid:57)(cid:36)(cid:55)(cid:50)(cid:400)
(cid:68)(cid:83)(cid:83)(cid:85)(cid:82)(cid:89)(cid:68)(cid:79)
(cid:11)(cid:41)(cid:39)(cid:36)(cid:12)
(cid:36)(cid:71)(cid:80)(cid:76)(cid:81)(cid:76)(cid:86)(cid:87)(cid:85)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)
(cid:68)(cid:71)(cid:88)(cid:79)(cid:87)(cid:86) (cid:90)(cid:76)(cid:87)(cid:75)(cid:90)(cid:76)(cid:87)(cid:75)(cid:90)(cid:76)(cid:87)(cid:75)
(cid:54)(cid:83)(cid:85)(cid:68)(cid:92) (cid:73)(cid:82)(cid:85)(cid:73)(cid:82)(cid:85)(cid:73)(cid:82)(cid:85) (cid:68)(cid:71)(cid:88)(cid:79)(cid:87)(cid:86)
(cid:11)(cid:72)(cid:86)(cid:78)(cid:72)(cid:87)(cid:68)(cid:80)(cid:76)(cid:81)(cid:72)(cid:12) (cid:38)(cid:44)(cid:44)(cid:44)(cid:38)(cid:44)(cid:44)(cid:44)(cid:38)(cid:44)(cid:44)(cid:44) (cid:49)(cid:68)(cid:86)(cid:68)(cid:79)(cid:49)(cid:68)(cid:86)(cid:68)(cid:79)(cid:49)(cid:68)(cid:86)(cid:68)(cid:79) (cid:54)(cid:83)(cid:85)(cid:68)(cid:92)
(cid:11)(cid:72)(cid:86)(cid:78)(cid:72)(cid:87)(cid:68)(cid:80)(cid:76)(cid:81)(cid:72)(cid:12)
(cid:11)(cid:72)(cid:86)(cid:78)(cid:72)(cid:87)(cid:68)(cid:80)(cid:76)(cid:81)(cid:72)(cid:12) (cid:38)(cid:44)(cid:44)(cid:44) (cid:49)(cid:68)(cid:86)(cid:68)(cid:79) (cid:54)(cid:83)(cid:85)(cid:68)(cid:92) (cid:73)(cid:82)(cid:85) (cid:68)(cid:71)(cid:88)(cid:79)(cid:87)(cid:86) (cid:90)(cid:76)(cid:87)(cid:75)
(cid:68)(cid:71)(cid:88)(cid:79)(cid:87)(cid:86)
(cid:54)(cid:83)(cid:85)(cid:68)(cid:92)
(cid:11)(cid:72)(cid:86)(cid:78)(cid:72)(cid:87)(cid:68)(cid:80)(cid:76)(cid:81)(cid:72)(cid:12)
Treatment Resistant Depression (TRD), who
Treatment Resistant Depression (TRD), who
Treatment Resistant Depression (TRD), who
Treatment Resistant Depression (TRD), who
have cycled through multiple treatments
have cycled through multiple treatments
have cycled through multiple treatments
have cycled through multiple treatments
without relief. TRD is a debilitating disease that 
without relief. TRD is a debilitating disease that 
without relief. TRD is a debilitating disease that
without relief. TRD is a debilitating disease that 
is associated with chronic health problems, and
is associated with chronic health problems, and
is associated with chronic health problems, and
is associated with chronic health problems, and
quite tragically, can lead to suicide if not treated
quite tragically, can lead to suicide if not treated
quite tragically, can lead to suicide if not treated
quite tragically, can lead to suicide if not treated
(cid:85)(cid:72)(cid:83)(cid:85)(cid:72)(cid:86)(cid:72)(cid:81)(cid:87)(cid:86) (cid:81)(cid:82)(cid:87)(cid:81)(cid:82)(cid:87)(cid:81)(cid:82)(cid:87) (cid:82)(cid:81)(cid:79)(cid:92)(cid:82)(cid:81)(cid:79)(cid:92)(cid:82)(cid:81)(cid:79)(cid:92) (cid:68)(cid:68)(cid:68) (cid:81)(cid:72)(cid:90)(cid:81)(cid:72)(cid:90)(cid:81)(cid:72)(cid:90)
(cid:54)(cid:51)(cid:53)(cid:36)(cid:57)(cid:36)(cid:55)(cid:50)(cid:400) (cid:85)(cid:72)(cid:83)(cid:85)(cid:72)(cid:86)(cid:72)(cid:81)(cid:87)(cid:86)
(cid:83)(cid:85)(cid:82)(cid:83)(cid:72)(cid:85)(cid:79)(cid:92)(cid:17) (cid:54)(cid:51)(cid:53)(cid:36)(cid:57)(cid:36)(cid:55)(cid:50)(cid:400)
(cid:83)(cid:85)(cid:82)(cid:83)(cid:72)(cid:85)(cid:79)(cid:92)(cid:17)
(cid:85)(cid:72)(cid:83)(cid:85)(cid:72)(cid:86)(cid:72)(cid:81)(cid:87)(cid:86)
(cid:54)(cid:51)(cid:53)(cid:36)(cid:57)(cid:36)(cid:55)(cid:50)(cid:400)
(cid:83)(cid:85)(cid:82)(cid:83)(cid:72)(cid:85)(cid:79)(cid:92)(cid:17)
(cid:83)(cid:85)(cid:82)(cid:83)(cid:72)(cid:85)(cid:79)(cid:92)(cid:17) (cid:54)(cid:51)(cid:53)(cid:36)(cid:57)(cid:36)(cid:55)(cid:50)(cid:400) (cid:85)(cid:72)(cid:83)(cid:85)(cid:72)(cid:86)(cid:72)(cid:81)(cid:87)(cid:86) (cid:81)(cid:82)(cid:87) (cid:82)(cid:81)(cid:79)(cid:92) (cid:68) (cid:81)(cid:72)(cid:90)
breakthrough medicine in our product portfolio, 
breakthrough medicine in our product portfolio, 
breakthrough medicine in our product portfolio,
breakthrough medicine in our product portfolio, 
but also a new hope for adults who suffer from
but also a new hope for adults who suffer from
but also a new hope for adults who suffer from
but also a new hope for adults who suffer from
TRD. It also offers the first new mechanism
TRD. It also offers the first new mechanism
TRD. It also offers the first new mechanism
TRD. It also offers the first new mechanism
of action to address TRD. And importantly, in
of action to address TRD. And importantly, in
of action to address TRD. And importantly, in
of action to address TRD. And importantly, in
accordance with risk mitigation guidance from
accordance with risk mitigation guidance from
accordance with risk mitigation guidance from
accordance with risk mitigation guidance from
(cid:54)(cid:51)(cid:53)(cid:36)(cid:57)(cid:36)(cid:55)(cid:50)(cid:400) (cid:70)(cid:68)(cid:81)(cid:70)(cid:68)(cid:81)(cid:70)(cid:68)(cid:81) (cid:82)(cid:81)(cid:79)(cid:92)(cid:82)(cid:81)(cid:79)(cid:92)(cid:82)(cid:81)(cid:79)(cid:92) (cid:69)(cid:72)(cid:69)(cid:72)(cid:69)(cid:72) (cid:68)(cid:71)(cid:80)(cid:76)(cid:81)(cid:76)(cid:86)(cid:87)(cid:72)(cid:85)(cid:72)(cid:71)
(cid:41)(cid:39)(cid:36)(cid:15) (cid:54)(cid:51)(cid:53)(cid:36)(cid:57)(cid:36)(cid:55)(cid:50)(cid:400)
(cid:87)(cid:75)(cid:72)(cid:87)(cid:75)(cid:72)(cid:87)(cid:75)(cid:72) (cid:41)(cid:39)(cid:36)(cid:15)
(cid:87)(cid:75)(cid:72) (cid:41)(cid:39)(cid:36)(cid:15) (cid:54)(cid:51)(cid:53)(cid:36)(cid:57)(cid:36)(cid:55)(cid:50)(cid:400) (cid:70)(cid:68)(cid:81) (cid:82)(cid:81)(cid:79)(cid:92) (cid:69)(cid:72) (cid:68)(cid:71)(cid:80)(cid:76)(cid:81)(cid:76)(cid:86)(cid:87)(cid:72)(cid:85)(cid:72)(cid:71)
(cid:68)(cid:71)(cid:80)(cid:76)(cid:81)(cid:76)(cid:86)(cid:87)(cid:72)(cid:85)(cid:72)(cid:71)
(cid:68)(cid:71)(cid:80)(cid:76)(cid:81)(cid:76)(cid:86)(cid:87)(cid:72)(cid:85)(cid:72)(cid:71)
(cid:54)(cid:51)(cid:53)(cid:36)(cid:57)(cid:36)(cid:55)(cid:50)(cid:400)
(cid:41)(cid:39)(cid:36)(cid:15)
by certified treatment centers and will not be 
by certified treatment centers and will not be
by certified treatment centers and will not be 
by certified treatment centers and will not be 
dispensed directly to patients to take at home.
dispensed directly to patients to take at home.
dispensed directly to patients to take at home.
dispensed directly to patients to take at home.
We have listened with great intent to the concerns
We have listened with great intent to the concerns
We have listened with great intent to the concerns
We have listened with great intent to the concerns
voiced by many stakeholders over the pricing and
voiced by many stakeholders over the pricing and
voiced by many stakeholders over the pricing and
voiced by many stakeholders over the pricing and
transparency of products and our healthcare
transparency of products and our healthcare
transparency of products and our healthcare
transparency of products and our healthcare
(cid:44) (cid:57) (cid:3) (cid:373) (cid:3) (cid:38) (cid:43) (cid:36) (cid:44) (cid:53) (cid:48) (cid:36) (cid:49) (cid:366) (cid:54) (cid:3) (cid:47) (cid:40) (cid:55) (cid:55) (cid:40) (cid:53)

--- Page 7 ---
(cid:68)(cid:85)(cid:82)(cid:88)(cid:81)(cid:71) (cid:87)(cid:75)(cid:72)(cid:87)(cid:75)(cid:72)(cid:87)(cid:75)(cid:72)
(cid:54)(cid:87)(cid:68)(cid:87)(cid:72)(cid:86) (cid:68)(cid:81)(cid:71)(cid:68)(cid:81)(cid:71)(cid:68)(cid:81)(cid:71) (cid:68)(cid:85)(cid:82)(cid:88)(cid:81)(cid:71)
(cid:56)(cid:81)(cid:76)(cid:87)(cid:72)(cid:71) (cid:54)(cid:87)(cid:68)(cid:87)(cid:72)(cid:86)
(cid:86)(cid:92)(cid:86)(cid:87)(cid:72)(cid:80)(cid:86) (cid:76)(cid:81)(cid:76)(cid:81)(cid:76)(cid:81) (cid:87)(cid:75)(cid:72)(cid:87)(cid:75)(cid:72)(cid:87)(cid:75)(cid:72) (cid:56)(cid:81)(cid:76)(cid:87)(cid:72)(cid:71)
(cid:86)(cid:92)(cid:86)(cid:87)(cid:72)(cid:80)(cid:86)
(cid:86)(cid:92)(cid:86)(cid:87)(cid:72)(cid:80)(cid:86) (cid:76)(cid:81) (cid:87)(cid:75)(cid:72) (cid:56)(cid:81)(cid:76)(cid:87)(cid:72)(cid:71) (cid:54)(cid:87)(cid:68)(cid:87)(cid:72)(cid:86) (cid:68)(cid:81)(cid:71) (cid:68)(cid:85)(cid:82)(cid:88)(cid:81)(cid:71) (cid:87)(cid:75)(cid:72)
(cid:68)(cid:85)(cid:82)(cid:88)(cid:81)(cid:71)
(cid:54)(cid:87)(cid:68)(cid:87)(cid:72)(cid:86)
(cid:56)(cid:81)(cid:76)(cid:87)(cid:72)(cid:71)
(cid:86)(cid:92)(cid:86)(cid:87)(cid:72)(cid:80)(cid:86)
world. We are committed to taking the lead, 
world. We are committed to taking the lead,
world. We are committed to taking the lead, 
world. We are committed to taking the lead, 
being responsible partners and doing our part to 
being responsible partners and doing our part to 
being responsible partners and doing our part to
being responsible partners and doing our part to 
not only treat patients, but also ensure they can 
not only treat patients, but also ensure they can 
not only treat patients, but also ensure they can
not only treat patients, but also ensure they can 
get access in an open and affordable manner.
get access in an open and affordable manner.
get access in an open and affordable manner.
get access in an open and affordable manner.
As a result of direct interaction with patients,
As a result of direct interaction with patients,
As a result of direct interaction with patients,
As a result of direct interaction with patients,
their families and healthcare professionals 
their families and healthcare professionals
their families and healthcare professionals 
their families and healthcare professionals 
(cid:68)(cid:70)(cid:85)(cid:82)(cid:86)(cid:86) (cid:87)(cid:75)(cid:72)(cid:87)(cid:75)(cid:72)(cid:87)(cid:75)(cid:72) (cid:56)(cid:81)(cid:76)(cid:87)(cid:72)(cid:71)
(cid:88)(cid:83)(cid:82)(cid:81) (cid:87)(cid:75)(cid:72)(cid:87)(cid:75)(cid:72)(cid:87)(cid:75)(cid:72)
(cid:69)(cid:88)(cid:76)(cid:79)(cid:71)(cid:76)(cid:81)(cid:74) (cid:88)(cid:83)(cid:82)(cid:81)
(cid:54)(cid:87)(cid:68)(cid:87)(cid:72)(cid:86)(cid:15) (cid:68)(cid:81)(cid:71)(cid:68)(cid:81)(cid:71)(cid:68)(cid:81)(cid:71) (cid:69)(cid:88)(cid:76)(cid:79)(cid:71)(cid:76)(cid:81)(cid:74)
(cid:56)(cid:81)(cid:76)(cid:87)(cid:72)(cid:71) (cid:54)(cid:87)(cid:68)(cid:87)(cid:72)(cid:86)(cid:15)
(cid:68)(cid:70)(cid:85)(cid:82)(cid:86)(cid:86)
(cid:68)(cid:70)(cid:85)(cid:82)(cid:86)(cid:86) (cid:87)(cid:75)(cid:72) (cid:56)(cid:81)(cid:76)(cid:87)(cid:72)(cid:71) (cid:54)(cid:87)(cid:68)(cid:87)(cid:72)(cid:86)(cid:15) (cid:68)(cid:81)(cid:71) (cid:69)(cid:88)(cid:76)(cid:79)(cid:71)(cid:76)(cid:81)(cid:74) (cid:88)(cid:83)(cid:82)(cid:81) (cid:87)(cid:75)(cid:72)
(cid:88)(cid:83)(cid:82)(cid:81)
(cid:69)(cid:88)(cid:76)(cid:79)(cid:71)(cid:76)(cid:81)(cid:74)
(cid:54)(cid:87)(cid:68)(cid:87)(cid:72)(cid:86)(cid:15)
(cid:56)(cid:81)(cid:76)(cid:87)(cid:72)(cid:71)
(cid:68)(cid:70)(cid:85)(cid:82)(cid:86)(cid:86)
(cid:39)(cid:72)(cid:83)(cid:68)(cid:85)(cid:87)(cid:80)(cid:72)(cid:81)(cid:87) (cid:82)(cid:73)(cid:82)(cid:73)(cid:82)(cid:73)
(cid:83)(cid:85)(cid:82)(cid:83)(cid:82)(cid:86)(cid:68)(cid:79) (cid:73)(cid:85)(cid:82)(cid:80)(cid:73)(cid:85)(cid:82)(cid:80)(cid:73)(cid:85)(cid:82)(cid:80) (cid:87)(cid:75)(cid:72)(cid:87)(cid:75)(cid:72)(cid:87)(cid:75)(cid:72) (cid:56)(cid:17)(cid:54)(cid:17)(cid:56)(cid:17)(cid:54)(cid:17)(cid:56)(cid:17)(cid:54)(cid:17) (cid:39)(cid:72)(cid:83)(cid:68)(cid:85)(cid:87)(cid:80)(cid:72)(cid:81)(cid:87)
(cid:82)(cid:85)(cid:76)(cid:74)(cid:76)(cid:81)(cid:68)(cid:79) (cid:83)(cid:85)(cid:82)(cid:83)(cid:82)(cid:86)(cid:68)(cid:79)
(cid:82)(cid:85)(cid:76)(cid:74)(cid:76)(cid:81)(cid:68)(cid:79)
(cid:39)(cid:72)(cid:83)(cid:68)(cid:85)(cid:87)(cid:80)(cid:72)(cid:81)(cid:87)
(cid:83)(cid:85)(cid:82)(cid:83)(cid:82)(cid:86)(cid:68)(cid:79)
(cid:82)(cid:85)(cid:76)(cid:74)(cid:76)(cid:81)(cid:68)(cid:79)
(cid:82)(cid:85)(cid:76)(cid:74)(cid:76)(cid:81)(cid:68)(cid:79) (cid:83)(cid:85)(cid:82)(cid:83)(cid:82)(cid:86)(cid:68)(cid:79) (cid:73)(cid:85)(cid:82)(cid:80) (cid:87)(cid:75)(cid:72) (cid:56)(cid:17)(cid:54)(cid:17) (cid:39)(cid:72)(cid:83)(cid:68)(cid:85)(cid:87)(cid:80)(cid:72)(cid:81)(cid:87) (cid:82)(cid:73)
(cid:89)(cid:82)(cid:79)(cid:88)(cid:81)(cid:87)(cid:68)(cid:85)(cid:76)(cid:79)(cid:92) (cid:87)(cid:82)(cid:82)(cid:78)
(cid:54)(cid:72)(cid:85)(cid:89)(cid:76)(cid:70)(cid:72)(cid:86)(cid:15) (cid:90)(cid:72)(cid:90)(cid:72)(cid:90)(cid:72) (cid:89)(cid:82)(cid:79)(cid:88)(cid:81)(cid:87)(cid:68)(cid:85)(cid:76)(cid:79)(cid:92)
(cid:43)(cid:88)(cid:80)(cid:68)(cid:81) (cid:54)(cid:72)(cid:85)(cid:89)(cid:76)(cid:70)(cid:72)(cid:86)(cid:15)
(cid:43)(cid:72)(cid:68)(cid:79)(cid:87)(cid:75) (cid:68)(cid:81)(cid:71)(cid:68)(cid:81)(cid:71)(cid:68)(cid:81)(cid:71) (cid:43)(cid:88)(cid:80)(cid:68)(cid:81)
(cid:43)(cid:72)(cid:68)(cid:79)(cid:87)(cid:75)
(cid:43)(cid:72)(cid:68)(cid:79)(cid:87)(cid:75) (cid:68)(cid:81)(cid:71) (cid:43)(cid:88)(cid:80)(cid:68)(cid:81) (cid:54)(cid:72)(cid:85)(cid:89)(cid:76)(cid:70)(cid:72)(cid:86)(cid:15) (cid:90)(cid:72) (cid:89)(cid:82)(cid:79)(cid:88)(cid:81)(cid:87)(cid:68)(cid:85)(cid:76)(cid:79)(cid:92) (cid:87)(cid:82)(cid:82)(cid:78)
(cid:87)(cid:82)(cid:82)(cid:78)
(cid:87)(cid:82)(cid:82)(cid:78)
(cid:89)(cid:82)(cid:79)(cid:88)(cid:81)(cid:87)(cid:68)(cid:85)(cid:76)(cid:79)(cid:92)
(cid:54)(cid:72)(cid:85)(cid:89)(cid:76)(cid:70)(cid:72)(cid:86)(cid:15)
(cid:43)(cid:88)(cid:80)(cid:68)(cid:81)
(cid:43)(cid:72)(cid:68)(cid:79)(cid:87)(cid:75)
an important measure to help consumers gain a
an important measure to help consumers gain a
an important measure to help consumers gain a
an important measure to help consumers gain a
better picture of what they should expect to pay
better picture of what they should expect to pay
better picture of what they should expect to pay
better picture of what they should expect to pay
for their medicines. We have proposed including
for their medicines. We have proposed including
for their medicines. We have proposed including
for their medicines. We have proposed including
list-price information in direct-to-consumer TV
list-price information in direct-to-consumer TV
list-price information in direct-to-consumer TV
list-price information in direct-to-consumer TV
ads, starting with our most-prescribed medicine, 
ads, starting with our most-prescribed medicine, 
ads, starting with our most-prescribed medicine,
ads, starting with our most-prescribed medicine, 
XARELTO (rivaroxaban), an oral anti-coagulant. 
XARELTO (rivaroxaban), an oral anti-coagulant.
XARELTO (rivaroxaban), an oral anti-coagulant. 
XARELTO (rivaroxaban), an oral anti-coagulant. 
To ensure patients have clarity, we plan to
To ensure patients have clarity, we plan to
To ensure patients have clarity, we plan to
To ensure patients have clarity, we plan to
include both the list price and potential patient 
include both the list price and potential patient 
include both the list price and potential patient
include both the list price and potential patient 
out-of-pocket costs. We believe transparency is
out-of-pocket costs. We believe transparency is
out-of-pocket costs. We believe transparency is
out-of-pocket costs. We believe transparency is
a fundamental responsibility of this Company.
a fundamental responsibility of this Company.
a fundamental responsibility of this Company.
a fundamental responsibility of this Company.
It’s also another strong demonstration that
It’s also another strong demonstration that
It’s also another strong demonstration that
It’s also another strong demonstration that
our purpose, focused on helping patients, is 
our purpose, focused on helping patients, is 
our purpose, focused on helping patients, is
our purpose, focused on helping patients, is 
driving our business – just as it should be.
driving our business – just as it should be.
driving our business – just as it should be.
driving our business – just as it should be.
Our Pharmaceutical business has taken a strong 
Our Pharmaceutical business has taken a strong 
Our Pharmaceutical business has taken a strong
Our Pharmaceutical business has taken a strong 
leadership stance on increasing transparency
leadership stance on increasing transparency
leadership stance on increasing transparency
leadership stance on increasing transparency
in the industry. I am pleased to share we
in the industry. I am pleased to share we
in the industry. I am pleased to share we
in the industry. I am pleased to share we
(cid:45)(cid:68)(cid:81)(cid:86)(cid:86)(cid:72)(cid:81) (cid:56)(cid:17)(cid:54)(cid:17)(cid:56)(cid:17)(cid:54)(cid:17)(cid:56)(cid:17)(cid:54)(cid:17)
(cid:68)(cid:81)(cid:81)(cid:88)(cid:68)(cid:79) (cid:45)(cid:68)(cid:81)(cid:86)(cid:86)(cid:72)(cid:81)
(cid:85)(cid:72)(cid:79)(cid:72)(cid:68)(cid:86)(cid:72) (cid:82)(cid:88)(cid:85)(cid:82)(cid:88)(cid:85)(cid:82)(cid:88)(cid:85) (cid:87)(cid:75)(cid:76)(cid:85)(cid:71)(cid:87)(cid:75)(cid:76)(cid:85)(cid:71)(cid:87)(cid:75)(cid:76)(cid:85)(cid:71) (cid:68)(cid:81)(cid:81)(cid:88)(cid:68)(cid:79)
(cid:90)(cid:76)(cid:79)(cid:79)(cid:90)(cid:76)(cid:79)(cid:79)(cid:90)(cid:76)(cid:79)(cid:79) (cid:85)(cid:72)(cid:79)(cid:72)(cid:68)(cid:86)(cid:72)
(cid:90)(cid:76)(cid:79)(cid:79) (cid:85)(cid:72)(cid:79)(cid:72)(cid:68)(cid:86)(cid:72) (cid:82)(cid:88)(cid:85) (cid:87)(cid:75)(cid:76)(cid:85)(cid:71) (cid:68)(cid:81)(cid:81)(cid:88)(cid:68)(cid:79) (cid:45)(cid:68)(cid:81)(cid:86)(cid:86)(cid:72)(cid:81) (cid:56)(cid:17)(cid:54)(cid:17)
(cid:45)(cid:68)(cid:81)(cid:86)(cid:86)(cid:72)(cid:81)
(cid:68)(cid:81)(cid:81)(cid:88)(cid:68)(cid:79)
(cid:85)(cid:72)(cid:79)(cid:72)(cid:68)(cid:86)(cid:72)
Transparency Report in late March. This report, 
Transparency Report in late March. This report, 
Transparency Report in late March. This report,
Transparency Report in late March. This report, 
reflective of our actions in 2018, shows that our
reflective of our actions in 2018, shows that our
reflective of our actions in 2018, shows that our
reflective of our actions in 2018, shows that our
net prices have decreased again, by 6.8%.
net prices have decreased again, by 6.8%.
net prices have decreased again, by 6.8%.
net prices have decreased again, by 6.8%.
Consumer
Consumer
Consumer
Consumer
In 2018, fueled by our iconic brands and deep 
In 2018, fueled by our iconic brands and deep 
In 2018, fueled by our iconic brands and deep
In 2018, fueled by our iconic brands and deep 
consumer insights, our Consumer business
consumer insights, our Consumer business
consumer insights, our Consumer business
consumer insights, our Consumer business
achieved above-market growth. As we look 
achieved above-market growth. As we look
achieved above-market growth. As we look 
achieved above-market growth. As we look 
ahead, we will work to enhance our leadership
ahead, we will work to enhance our leadership
ahead, we will work to enhance our leadership
ahead, we will work to enhance our leadership
in priority categories by focusing on critical 
in priority categories by focusing on critical 
in priority categories by focusing on critical
in priority categories by focusing on critical 
geographies and our mega-brands, while also 
geographies and our mega-brands, while also 
geographies and our mega-brands, while also
geographies and our mega-brands, while also 
continuing to expand into the fast-growing 
continuing to expand into the fast-growing
continuing to expand into the fast-growing 
continuing to expand into the fast-growing 
naturals category. Our acquisition of Zarbee’s, Inc. 
naturals category. Our acquisition of Zarbee’s, Inc. 
naturals category. Our acquisition of Zarbee’s, Inc.
naturals category. Our acquisition of Zarbee’s, Inc. 
in OTC is a key example of this expanding focus.
in OTC is a key example of this expanding focus.
in OTC is a key example of this expanding focus.
in OTC is a key example of this expanding focus.
We have the strategies in place to move with the
We have the strategies in place to move with the
We have the strategies in place to move with the
We have the strategies in place to move with the
agility required to address evolving market needs. 
agility required to address evolving market needs. 
agility required to address evolving market needs.
agility required to address evolving market needs. 
We have adopted a multichannel approach, 
We have adopted a multichannel approach, 
We have adopted a multichannel approach,
We have adopted a multichannel approach, 
from the big-box retailers to e-commerce
from the big-box retailers to e-commerce
from the big-box retailers to e-commerce
from the big-box retailers to e-commerce
channels, to better serve our consumers. 
channels, to better serve our consumers.
channels, to better serve our consumers. 
channels, to better serve our consumers. 
The results of our continual connection with 
The results of our continual connection with 
The results of our continual connection with
The results of our continual connection with
consumers can be seen in the global relaunch of 
consumers can be seen in the global relaunch of
consumers can be seen in the global relaunch of 
consumers can be seen in the global relaunch of 
(cid:83)(cid:85)(cid:82)(cid:71)(cid:88)(cid:70)(cid:87)(cid:86) (cid:76)(cid:81)(cid:76)(cid:81)(cid:76)(cid:81) (cid:21)(cid:19)(cid:20)(cid:27)(cid:17)
(cid:45)(cid:50)(cid:43)(cid:49)(cid:54)(cid:50)(cid:49)(cid:366)(cid:86) (cid:37)(cid:68)(cid:69)(cid:92)(cid:37)(cid:68)(cid:69)(cid:92)(cid:37)(cid:68)(cid:69)(cid:92) (cid:79)(cid:76)(cid:81)(cid:72)(cid:79)(cid:76)(cid:81)(cid:72)(cid:79)(cid:76)(cid:81)(cid:72) (cid:82)(cid:73)(cid:82)(cid:73)(cid:82)(cid:73) (cid:83)(cid:85)(cid:82)(cid:71)(cid:88)(cid:70)(cid:87)(cid:86)
(cid:82)(cid:88)(cid:85)(cid:82)(cid:88)(cid:85)(cid:82)(cid:88)(cid:85) (cid:45)(cid:50)(cid:43)(cid:49)(cid:54)(cid:50)(cid:49)(cid:366)(cid:86)
(cid:21)(cid:19)(cid:20)(cid:27)(cid:17)
(cid:82)(cid:88)(cid:85) (cid:45)(cid:50)(cid:43)(cid:49)(cid:54)(cid:50)(cid:49)(cid:366)(cid:86) (cid:37)(cid:68)(cid:69)(cid:92) (cid:79)(cid:76)(cid:81)(cid:72) (cid:82)(cid:73) (cid:83)(cid:85)(cid:82)(cid:71)(cid:88)(cid:70)(cid:87)(cid:86) (cid:76)(cid:81) (cid:21)(cid:19)(cid:20)(cid:27)(cid:17)
(cid:21)(cid:19)(cid:20)(cid:27)(cid:17)
(cid:83)(cid:85)(cid:82)(cid:71)(cid:88)(cid:70)(cid:87)(cid:86)
(cid:45)(cid:50)(cid:43)(cid:49)(cid:54)(cid:50)(cid:49)(cid:366)(cid:86)
We are committed to disclosing 100% of our 
We are committed to disclosing 100% of our
We are committed to disclosing 100% of our 
We are committed to disclosing 100% of our 
fragrance ingredients above 100 parts per million 
fragrance ingredients above 100 parts per million 
fragrance ingredients above 100 parts per million
fragrance ingredients above 100 parts per million 
(ppm) in our shampoos, washes and lotions. 
(ppm) in our shampoos, washes and lotions.
(ppm) in our shampoos, washes and lotions. 
(ppm) in our shampoos, washes and lotions. 
And we’ve been recognized for this greater 
And we’ve been recognized for this greater 
And we’ve been recognized for this greater
And we’ve been recognized for this greater 
transparency by The Environmental Working
transparency by The Environmental Working
transparency by The Environmental Working
transparency by The Environmental Working
Group. Our relaunch also includes new packaging 
Group. Our relaunch also includes new packaging 
Group. Our relaunch also includes new packaging
Group. Our relaunch also includes new packaging 
and informational social media communications 
and informational social media communications
and informational social media communications
and informational social media communications 
tailored to the needs and wants of millennial 
tailored to the needs and wants of millennial
tailored to the needs and wants of millennial 
tailored to the needs and wants of millennial
(cid:45)(cid:50)(cid:43)(cid:49)(cid:54)(cid:50)(cid:49)(cid:366)(cid:86) (cid:37)(cid:68)(cid:69)(cid:92)(cid:37)(cid:68)(cid:69)(cid:92)(cid:37)(cid:68)(cid:69)(cid:92)
(cid:74)(cid:79)(cid:82)(cid:69)(cid:68)(cid:79) (cid:45)(cid:50)(cid:43)(cid:49)(cid:54)(cid:50)(cid:49)(cid:366)(cid:86)
(cid:71)(cid:68)(cid:71)(cid:86)(cid:17) (cid:50)(cid:88)(cid:85)(cid:50)(cid:88)(cid:85)(cid:50)(cid:88)(cid:85) (cid:74)(cid:79)(cid:82)(cid:69)(cid:68)(cid:79)
(cid:80)(cid:82)(cid:80)(cid:86)(cid:80)(cid:82)(cid:80)(cid:86)(cid:80)(cid:82)(cid:80)(cid:86) (cid:68)(cid:81)(cid:71)(cid:68)(cid:81)(cid:71)(cid:68)(cid:81)(cid:71) (cid:71)(cid:68)(cid:71)(cid:86)(cid:17)
(cid:80)(cid:82)(cid:80)(cid:86) (cid:68)(cid:81)(cid:71) (cid:71)(cid:68)(cid:71)(cid:86)(cid:17) (cid:50)(cid:88)(cid:85) (cid:74)(cid:79)(cid:82)(cid:69)(cid:68)(cid:79) (cid:45)(cid:50)(cid:43)(cid:49)(cid:54)(cid:50)(cid:49)(cid:366)(cid:86) (cid:37)(cid:68)(cid:69)(cid:92)
(cid:45)(cid:50)(cid:43)(cid:49)(cid:54)(cid:50)(cid:49)(cid:366)(cid:86)
(cid:74)(cid:79)(cid:82)(cid:69)(cid:68)(cid:79)
(cid:71)(cid:68)(cid:71)(cid:86)(cid:17)
relaunch is off to a solid start and we will continue
relaunch is off to a solid start and we will continue
relaunch is off to a solid start and we will continue
relaunch is off to a solid start and we will continue
to launch across global markets throughout 2019.
to launch across global markets throughout 2019.
to launch across global markets throughout 2019.
to launch across global markets throughout 2019.
Additionally, in response to our consumers asking
Additionally, in response to our consumers asking
Additionally, in response to our consumers asking
Additionally, in response to our consumers asking
for personalized skincare solutions that address
for personalized skincare solutions that address
for personalized skincare solutions that address
for personalized skincare solutions that address
their skin’s unique needs, we are developing
their skin’s unique needs, we are developing
their skin’s unique needs, we are developing
their skin’s unique needs, we are developing
our most personalized skincare product to
our most personalized skincare product to
our most personalized skincare product to
our most personalized skincare product to
(cid:48)(cid:68)(cid:86)(cid:78)(cid:76)(cid:39)(cid:17) (cid:55)(cid:75)(cid:76)(cid:86)(cid:55)(cid:75)(cid:76)(cid:86)(cid:55)(cid:75)(cid:76)(cid:86)
(cid:49)(cid:40)(cid:56)(cid:55)(cid:53)(cid:50)(cid:42)(cid:40)(cid:49)(cid:36) (cid:48)(cid:68)(cid:86)(cid:78)(cid:76)(cid:39)(cid:17)
(cid:70)(cid:68)(cid:79)(cid:79)(cid:72)(cid:71) (cid:87)(cid:75)(cid:72)(cid:87)(cid:75)(cid:72)(cid:87)(cid:75)(cid:72) (cid:49)(cid:40)(cid:56)(cid:55)(cid:53)(cid:50)(cid:42)(cid:40)(cid:49)(cid:36)
(cid:71)(cid:68)(cid:87)(cid:72)(cid:15) (cid:70)(cid:68)(cid:79)(cid:79)(cid:72)(cid:71)
(cid:71)(cid:68)(cid:87)(cid:72)(cid:15)
(cid:71)(cid:68)(cid:87)(cid:72)(cid:15) (cid:70)(cid:68)(cid:79)(cid:79)(cid:72)(cid:71) (cid:87)(cid:75)(cid:72) (cid:49)(cid:40)(cid:56)(cid:55)(cid:53)(cid:50)(cid:42)(cid:40)(cid:49)(cid:36) (cid:48)(cid:68)(cid:86)(cid:78)(cid:76)(cid:39)(cid:17) (cid:55)(cid:75)(cid:76)(cid:86)
(cid:48)(cid:68)(cid:86)(cid:78)(cid:76)(cid:39)(cid:17)
(cid:49)(cid:40)(cid:56)(cid:55)(cid:53)(cid:50)(cid:42)(cid:40)(cid:49)(cid:36)
(cid:70)(cid:68)(cid:79)(cid:79)(cid:72)(cid:71)
(cid:71)(cid:68)(cid:87)(cid:72)(cid:15)
3D-printed sheet mask is inspired by user data
3D-printed sheet mask is inspired by user data
3D-printed sheet mask is inspired by user data
3D-printed sheet mask is inspired by user data
and will deliver the clinical efficacy expected 
and will deliver the clinical efficacy expected
and will deliver the clinical efficacy expected 
and will deliver the clinical efficacy expected 
from the #1 dermatologist-recommended
from the #1 dermatologist-recommended
from the #1 dermatologist-recommended
from the #1 dermatologist-recommended
(cid:49)(cid:40)(cid:56)(cid:55)(cid:53)(cid:50)(cid:42)(cid:40)(cid:49)(cid:36) (cid:69)(cid:85)(cid:68)(cid:81)(cid:71)
(cid:69)(cid:85)(cid:68)(cid:81)(cid:71) (cid:76)(cid:81)(cid:76)(cid:81)(cid:76)(cid:81) (cid:87)(cid:75)(cid:72)(cid:87)(cid:75)(cid:72)(cid:87)(cid:75)(cid:72) (cid:56)(cid:17)(cid:54)(cid:17)(cid:56)(cid:17)(cid:54)(cid:17)(cid:56)(cid:17)(cid:54)(cid:17) (cid:50)(cid:88)(cid:85)(cid:50)(cid:88)(cid:85)(cid:50)(cid:88)(cid:85) (cid:49)(cid:40)(cid:56)(cid:55)(cid:53)(cid:50)(cid:42)(cid:40)(cid:49)(cid:36)
(cid:69)(cid:85)(cid:68)(cid:81)(cid:71)
(cid:69)(cid:85)(cid:68)(cid:81)(cid:71) (cid:76)(cid:81) (cid:87)(cid:75)(cid:72) (cid:56)(cid:17)(cid:54)(cid:17) (cid:50)(cid:88)(cid:85) (cid:49)(cid:40)(cid:56)(cid:55)(cid:53)(cid:50)(cid:42)(cid:40)(cid:49)(cid:36) (cid:69)(cid:85)(cid:68)(cid:81)(cid:71)
(cid:69)(cid:85)(cid:68)(cid:81)(cid:71)
(cid:69)(cid:85)(cid:68)(cid:81)(cid:71)
(cid:49)(cid:40)(cid:56)(cid:55)(cid:53)(cid:50)(cid:42)(cid:40)(cid:49)(cid:36)
(cid:69)(cid:85)(cid:68)(cid:81)(cid:71)
is already globally recognized for delivering
is already globally recognized for delivering
is already globally recognized for delivering
is already globally recognized for delivering
topical skincare solutions at the intersection
topical skincare solutions at the intersection
topical skincare solutions at the intersection
topical skincare solutions at the intersection
of science and technology. This new product
of science and technology. This new product
of science and technology. This new product
of science and technology. This new product
will represent one further step toward a new 
will represent one further step toward a new 
will represent one further step toward a new
will represent one further step toward a new 
model of product development where we find 
model of product development where we find
model of product development where we find 
model of product development where we find 
creative uses for the latest technology, such as 
creative uses for the latest technology, such as 
creative uses for the latest technology, such as
creative uses for the latest technology, such as 
digital imaging, skin analysis and 3D printing,
digital imaging, skin analysis and 3D printing,
digital imaging, skin analysis and 3D printing,
digital imaging, skin analysis and 3D printing,
to give consumers new ways to achieve their 
to give consumers new ways to achieve their 
to give consumers new ways to achieve their
to give consumers new ways to achieve their 
best skincare possible. It is also a great example
best skincare possible. It is also a great example
best skincare possible. It is also a great example
best skincare possible. It is also a great example
of how we are leveraging innovation across 
of how we are leveraging innovation across 
of how we are leveraging innovation across
of how we are leveraging innovation across 
our business segments, as our 3D printing
our business segments, as our 3D printing
our business segments, as our 3D printing
our business segments, as our 3D printing
capability originated within Medical Devices.
capability originated within Medical Devices.
capability originated within Medical Devices.
capability originated within Medical Devices.
Medical Devices
Medical Devices
Medical Devices
Medical Devices
Our Medical Devices businesses are among the
Our Medical Devices businesses are among the
Our Medical Devices businesses are among the
Our Medical Devices businesses are among the
most diverse and successful in the healthcare
most diverse and successful in the healthcare
most diverse and successful in the healthcare
most diverse and successful in the healthcare
industry. At the same time, we fully recognize
industry. At the same time, we fully recognize
industry. At the same time, we fully recognize
industry. At the same time, we fully recognize
that our progress has not been uniform across
that our progress has not been uniform across
that our progress has not been uniform across
that our progress has not been uniform across
the Medical Devices portfolio. We have many 
the Medical Devices portfolio. We have many 
the Medical Devices portfolio. We have many
the Medical Devices portfolio. We have many 
areas of particularly strong performance such
areas of particularly strong performance such
areas of particularly strong performance such
areas of particularly strong performance such
as Electrophysiology, Vision Care, Wound
as Electrophysiology, Vision Care, Wound
as Electrophysiology, Vision Care, Wound
as Electrophysiology, Vision Care, Wound
(cid:87)(cid:75)(cid:72)(cid:85)(cid:72) (cid:68)(cid:85)(cid:72)(cid:68)(cid:85)(cid:72)(cid:68)(cid:85)(cid:72)
(cid:43)(cid:82)(cid:90)(cid:72)(cid:89)(cid:72)(cid:85)(cid:15) (cid:87)(cid:75)(cid:72)(cid:85)(cid:72)
(cid:37)(cid:76)(cid:82)(cid:16)(cid:54)(cid:88)(cid:85)(cid:74)(cid:72)(cid:85)(cid:92)(cid:17) (cid:43)(cid:82)(cid:90)(cid:72)(cid:89)(cid:72)(cid:85)(cid:15)
(cid:38)(cid:79)(cid:82)(cid:86)(cid:88)(cid:85)(cid:72)(cid:15) (cid:68)(cid:81)(cid:71)(cid:68)(cid:81)(cid:71)(cid:68)(cid:81)(cid:71) (cid:37)(cid:76)(cid:82)(cid:16)(cid:54)(cid:88)(cid:85)(cid:74)(cid:72)(cid:85)(cid:92)(cid:17)
(cid:38)(cid:79)(cid:82)(cid:86)(cid:88)(cid:85)(cid:72)(cid:15)
(cid:38)(cid:79)(cid:82)(cid:86)(cid:88)(cid:85)(cid:72)(cid:15) (cid:68)(cid:81)(cid:71) (cid:37)(cid:76)(cid:82)(cid:16)(cid:54)(cid:88)(cid:85)(cid:74)(cid:72)(cid:85)(cid:92)(cid:17) (cid:43)(cid:82)(cid:90)(cid:72)(cid:89)(cid:72)(cid:85)(cid:15) (cid:87)(cid:75)(cid:72)(cid:85)(cid:72) (cid:68)(cid:85)(cid:72)
(cid:87)(cid:75)(cid:72)(cid:85)(cid:72)
(cid:43)(cid:82)(cid:90)(cid:72)(cid:89)(cid:72)(cid:85)(cid:15)
(cid:37)(cid:76)(cid:82)(cid:16)(cid:54)(cid:88)(cid:85)(cid:74)(cid:72)(cid:85)(cid:92)(cid:17)
(cid:38)(cid:79)(cid:82)(cid:86)(cid:88)(cid:85)(cid:72)(cid:15)
also areas where we must improve, specifically
also areas where we must improve, specifically
also areas where we must improve, specifically
also areas where we must improve, specifically
within Orthopaedics. We demonstrated progress
within Orthopaedics. We demonstrated progress
within Orthopaedics. We demonstrated progress
within Orthopaedics. We demonstrated progress
throughout 2018 with the performance of our 
throughout 2018 with the performance of our
throughout 2018 with the performance of our 
throughout 2018 with the performance of our 
knee and spine businesses and we believe 
knee and spine businesses and we believe 
knee and spine businesses and we believe
knee and spine businesses and we believe 
this positions us well for 2019 and beyond. 
this positions us well for 2019 and beyond.
this positions us well for 2019 and beyond. 
this positions us well for 2019 and beyond. 
In 2018 we improved operational growth
In 2018 we improved operational growth
In 2018 we improved operational growth
In 2018 we improved operational growth
excluding acquisitions and divestitures by 
excluding acquisitions and divestitures by 
excluding acquisitions and divestitures by
excluding acquisitions and divestitures by 
1.1%*, as compared to 2017. Additionally, 
1.1%*, as compared to 2017. Additionally, 
1.1%*, as compared to 2017. Additionally,
1.1%*, as compared to 2017. Additionally, 
we improved our cadence of innovation by
we improved our cadence of innovation by
we improved our cadence of innovation by
we improved our cadence of innovation by
delivering 21 major product launches in 2018.
delivering 21 major product launches in 2018.
delivering 21 major product launches in 2018.
delivering 21 major product launches in 2018.
(cid:38) (cid:43) (cid:36) (cid:44) (cid:53) (cid:48) (cid:36) (cid:49) (cid:366) (cid:54) (cid:3) (cid:47) (cid:40) (cid:55) (cid:55) (cid:40) (cid:53) (cid:3) (cid:373) (cid:3) (cid:57)

--- Page 8 ---
One example is the launch of the EMBOTRAP 
One example is the launch of the EMBOTRAP 
One example is the launch of the EMBOTRAP
One example is the launch of the EMBOTRAP 
II Revascularization Device, a next-generation 
II Revascularization Device, a next-generation
II Revascularization Device, a next-generation 
II Revascularization Device, a next-generation 
stent retriever used to capture and remove 
stent retriever used to capture and remove 
stent retriever used to capture and remove
stent retriever used to capture and remove 
life-threatening blood clots from the brain 
life-threatening blood clots from the brain 
life-threatening blood clots from the brain
life-threatening blood clots from the brain 
following an ischemic stroke. We received 
following an ischemic stroke. We received 
following an ischemic stroke. We received
following an ischemic stroke. We received 
FDA clearance to market the mechanical clot 
FDA clearance to market the mechanical clot
FDA clearance to market the mechanical clot
FDA clearance to market the mechanical clot 
removal, or thrombectomy device, last May.
removal, or thrombectomy device, last May.
removal, or thrombectomy device, last May.
removal, or thrombectomy device, last May.
In 2019, we plan to launch 20 to 25 major 
In 2019, we plan to launch 20 to 25 major
In 2019, we plan to launch 20 to 25 major 
In 2019, we plan to launch 20 to 25 major 
(cid:50)(cid:36)(cid:54)(cid:60)(cid:54) (cid:90)(cid:76)(cid:87)(cid:75)(cid:90)(cid:76)(cid:87)(cid:75)(cid:90)(cid:76)(cid:87)(cid:75)
(cid:36)(cid:38)(cid:56)(cid:57)(cid:56)(cid:40) (cid:50)(cid:36)(cid:54)(cid:60)(cid:54)
(cid:76)(cid:81)(cid:70)(cid:79)(cid:88)(cid:71)(cid:76)(cid:81)(cid:74) (cid:36)(cid:38)(cid:56)(cid:57)(cid:56)(cid:40)
(cid:83)(cid:85)(cid:82)(cid:71)(cid:88)(cid:70)(cid:87)(cid:86)(cid:15) (cid:76)(cid:81)(cid:70)(cid:79)(cid:88)(cid:71)(cid:76)(cid:81)(cid:74)
(cid:83)(cid:85)(cid:82)(cid:71)(cid:88)(cid:70)(cid:87)(cid:86)(cid:15)
(cid:83)(cid:85)(cid:82)(cid:71)(cid:88)(cid:70)(cid:87)(cid:86)(cid:15) (cid:76)(cid:81)(cid:70)(cid:79)(cid:88)(cid:71)(cid:76)(cid:81)(cid:74) (cid:36)(cid:38)(cid:56)(cid:57)(cid:56)(cid:40) (cid:50)(cid:36)(cid:54)(cid:60)(cid:54) (cid:90)(cid:76)(cid:87)(cid:75)
(cid:50)(cid:36)(cid:54)(cid:60)(cid:54)
(cid:36)(cid:38)(cid:56)(cid:57)(cid:56)(cid:40)
(cid:76)(cid:81)(cid:70)(cid:79)(cid:88)(cid:71)(cid:76)(cid:81)(cid:74)
(cid:83)(cid:85)(cid:82)(cid:71)(cid:88)(cid:70)(cid:87)(cid:86)(cid:15)
(cid:44)(cid:81)(cid:87)(cid:72)(cid:79)(cid:79)(cid:76)(cid:74)(cid:72)(cid:81)(cid:87) (cid:55)(cid:72)(cid:70)(cid:75)(cid:81)(cid:82)(cid:79)(cid:82)(cid:74)(cid:92)(cid:400)(cid:15)
(cid:47)(cid:76)(cid:74)(cid:75)(cid:87) (cid:44)(cid:81)(cid:87)(cid:72)(cid:79)(cid:79)(cid:76)(cid:74)(cid:72)(cid:81)(cid:87)
(cid:55)(cid:85)(cid:68)(cid:81)(cid:86)(cid:76)(cid:87)(cid:76)(cid:82)(cid:81)(cid:86)(cid:400) (cid:47)(cid:76)(cid:74)(cid:75)(cid:87)
(cid:55)(cid:85)(cid:68)(cid:81)(cid:86)(cid:76)(cid:87)(cid:76)(cid:82)(cid:81)(cid:86)(cid:400)
(cid:55)(cid:85)(cid:68)(cid:81)(cid:86)(cid:76)(cid:87)(cid:76)(cid:82)(cid:81)(cid:86)(cid:400) (cid:47)(cid:76)(cid:74)(cid:75)(cid:87) (cid:44)(cid:81)(cid:87)(cid:72)(cid:79)(cid:79)(cid:76)(cid:74)(cid:72)(cid:81)(cid:87) (cid:55)(cid:72)(cid:70)(cid:75)(cid:81)(cid:82)(cid:79)(cid:82)(cid:74)(cid:92)(cid:400)(cid:15)
(cid:55)(cid:72)(cid:70)(cid:75)(cid:81)(cid:82)(cid:79)(cid:82)(cid:74)(cid:92)(cid:400)(cid:15)
(cid:55)(cid:72)(cid:70)(cid:75)(cid:81)(cid:82)(cid:79)(cid:82)(cid:74)(cid:92)(cid:400)(cid:15)
(cid:44)(cid:81)(cid:87)(cid:72)(cid:79)(cid:79)(cid:76)(cid:74)(cid:72)(cid:81)(cid:87)
(cid:47)(cid:76)(cid:74)(cid:75)(cid:87)
(cid:55)(cid:85)(cid:68)(cid:81)(cid:86)(cid:76)(cid:87)(cid:76)(cid:82)(cid:81)(cid:86)(cid:400)
a first-of-its-kind contact lens that was named 
a first-of-its-kind contact lens that was named 
a first-of-its-kind contact lens that was named
a first-of-its-kind contact lens that was named
one of TIME Magazine’s Best Inventions of 2018. 
one of TIME Magazine’s Best Inventions of 2018.
one of TIME Magazine’s Best Inventions of 2018. 
one of TIME Magazine’s Best Inventions of 2018. 
(cid:40)(cid:38)(cid:43)(cid:40)(cid:47)(cid:50)(cid:49) (cid:38)(cid:44)(cid:53)(cid:38)(cid:56)(cid:47)(cid:36)(cid:53)
(cid:72)(cid:91)(cid:68)(cid:80)(cid:83)(cid:79)(cid:72) (cid:76)(cid:86)(cid:76)(cid:86)(cid:76)(cid:86) (cid:87)(cid:75)(cid:72)(cid:87)(cid:75)(cid:72)(cid:87)(cid:75)(cid:72) (cid:40)(cid:38)(cid:43)(cid:40)(cid:47)(cid:50)(cid:49)
(cid:36)(cid:81)(cid:82)(cid:87)(cid:75)(cid:72)(cid:85) (cid:72)(cid:91)(cid:68)(cid:80)(cid:83)(cid:79)(cid:72)
(cid:36)(cid:81)(cid:82)(cid:87)(cid:75)(cid:72)(cid:85)
(cid:38)(cid:44)(cid:53)(cid:38)(cid:56)(cid:47)(cid:36)(cid:53)
(cid:36)(cid:81)(cid:82)(cid:87)(cid:75)(cid:72)(cid:85) (cid:72)(cid:91)(cid:68)(cid:80)(cid:83)(cid:79)(cid:72) (cid:76)(cid:86) (cid:87)(cid:75)(cid:72) (cid:40)(cid:38)(cid:43)(cid:40)(cid:47)(cid:50)(cid:49) (cid:38)(cid:44)(cid:53)(cid:38)(cid:56)(cid:47)(cid:36)(cid:53)
(cid:38)(cid:44)(cid:53)(cid:38)(cid:56)(cid:47)(cid:36)(cid:53)
(cid:40)(cid:38)(cid:43)(cid:40)(cid:47)(cid:50)(cid:49)
(cid:72)(cid:91)(cid:68)(cid:80)(cid:83)(cid:79)(cid:72)
(cid:36)(cid:81)(cid:82)(cid:87)(cid:75)(cid:72)(cid:85)
(cid:74)(cid:72)(cid:81)(cid:72)(cid:85)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81) (cid:87)(cid:72)(cid:70)(cid:75)(cid:81)(cid:82)(cid:79)(cid:82)(cid:74)(cid:92)
(cid:54)(cid:87)(cid:68)(cid:83)(cid:79)(cid:72)(cid:85)(cid:15) (cid:68)(cid:68)(cid:68) (cid:81)(cid:72)(cid:91)(cid:87)(cid:81)(cid:72)(cid:91)(cid:87)(cid:81)(cid:72)(cid:91)(cid:87) (cid:74)(cid:72)(cid:81)(cid:72)(cid:85)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)
(cid:51)(cid:82)(cid:90)(cid:72)(cid:85)(cid:72)(cid:71) (cid:54)(cid:87)(cid:68)(cid:83)(cid:79)(cid:72)(cid:85)(cid:15)
(cid:51)(cid:82)(cid:90)(cid:72)(cid:85)(cid:72)(cid:71)
(cid:51)(cid:82)(cid:90)(cid:72)(cid:85)(cid:72)(cid:71) (cid:54)(cid:87)(cid:68)(cid:83)(cid:79)(cid:72)(cid:85)(cid:15) (cid:68) (cid:81)(cid:72)(cid:91)(cid:87) (cid:74)(cid:72)(cid:81)(cid:72)(cid:85)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81) (cid:87)(cid:72)(cid:70)(cid:75)(cid:81)(cid:82)(cid:79)(cid:82)(cid:74)(cid:92)
(cid:87)(cid:72)(cid:70)(cid:75)(cid:81)(cid:82)(cid:79)(cid:82)(cid:74)(cid:92)
(cid:87)(cid:72)(cid:70)(cid:75)(cid:81)(cid:82)(cid:79)(cid:82)(cid:74)(cid:92)
(cid:74)(cid:72)(cid:81)(cid:72)(cid:85)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)
(cid:54)(cid:87)(cid:68)(cid:83)(cid:79)(cid:72)(cid:85)(cid:15)
(cid:51)(cid:82)(cid:90)(cid:72)(cid:85)(cid:72)(cid:71)
to reduce complications in colorectal, gastric 
to reduce complications in colorectal, gastric 
to reduce complications in colorectal, gastric
to reduce complications in colorectal, gastric 
and thoracic cancer surgeries. Clearly, 
and thoracic cancer surgeries. Clearly, 
and thoracic cancer surgeries. Clearly,
and thoracic cancer surgeries. Clearly, 
advancing our strategy in digital surgery is a 
advancing our strategy in digital surgery is a
advancing our strategy in digital surgery is a 
advancing our strategy in digital surgery is a 
major investment for our future. Our digital
major investment for our future. Our digital
major investment for our future. Our digital
major investment for our future. Our digital
surgery platform is being designed to combine 
surgery platform is being designed to combine 
surgery platform is being designed to combine
surgery platform is being designed to combine 
robotics, advanced instrumentation and data 
robotics, advanced instrumentation and data 
robotics, advanced instrumentation and data
robotics, advanced instrumentation and data 
analytics to enable better patient outcomes by 
analytics to enable better patient outcomes by
analytics to enable better patient outcomes by 
analytics to enable better patient outcomes by 
improving access to minimally invasive surgery 
improving access to minimally invasive surgery 
improving access to minimally invasive surgery
improving access to minimally invasive surgery 
and helping to reduce the cost of care. 
and helping to reduce the cost of care.
and helping to reduce the cost of care. 
and helping to reduce the cost of care. 
As we capitalize on our comprehensive
As we capitalize on our comprehensive
As we capitalize on our comprehensive
As we capitalize on our comprehensive
portfolio and an accelerated growth strategy,
portfolio and an accelerated growth strategy,
portfolio and an accelerated growth strategy,
portfolio and an accelerated growth strategy,
we are committed to improving performance 
we are committed to improving performance 
we are committed to improving performance
we are committed to improving performance 
across our Medical Devices business.
across our Medical Devices business.
across our Medical Devices business.
across our Medical Devices business.
While we are pleased with our 2018 performance, 
While we are pleased with our 2018 performance, 
While we are pleased with our 2018 performance,
While we are pleased with our 2018 performance, 
we are never satisfied. Looking ahead, we are
we are never satisfied. Looking ahead, we are
we are never satisfied. Looking ahead, we are
we are never satisfied. Looking ahead, we are
committed to advancing the innovation pipeline
committed to advancing the innovation pipeline
committed to advancing the innovation pipeline
committed to advancing the innovation pipeline
in our Pharmaceutical business, broadening the 
in our Pharmaceutical business, broadening the
in our Pharmaceutical business, broadening the 
in our Pharmaceutical business, broadening the 
reach of our Consumer business and meeting the
reach of our Consumer business and meeting the
reach of our Consumer business and meeting the
reach of our Consumer business and meeting the
full potential of our Medical Devices business.
full potential of our Medical Devices business.
full potential of our Medical Devices business.
full potential of our Medical Devices business.
I want to emphasize that product quality  
and safety are not only top business priorities 
for Johnson & Johnson, they are also core 
obligations embodied in Our Credo. 
Leading With Certainty
Leading With Certainty
Leading With Certainty
Leading With Certainty
The volume and speed of change around the 
The volume and speed of change around the
The volume and speed of change around the 
The volume and speed of change around the 
world and across all business industries is 
world and across all business industries is 
world and across all business industries is
world and across all business industries is
the new normal. The velocity of this change 
the new normal. The velocity of this change 
the new normal. The velocity of this change
the new normal. The velocity of this change 
is apparent with circumstances like the
is apparent with circumstances like the
is apparent with circumstances like the
is apparent with circumstances like the
evolving geopolitical landscape, ongoing
evolving geopolitical landscape, ongoing
evolving geopolitical landscape, ongoing
evolving geopolitical landscape, ongoing
market volatility, rising pressure to reduce
market volatility, rising pressure to reduce
market volatility, rising pressure to reduce
market volatility, rising pressure to reduce
pricing, rapid entry of disruptive technologies, 
pricing, rapid entry of disruptive technologies, 
pricing, rapid entry of disruptive technologies,
pricing, rapid entry of disruptive technologies, 
a crowded competitive marketplace, and an
a crowded competitive marketplace, and an
a crowded competitive marketplace, and an
a crowded competitive marketplace, and an
expanding range of customer preferences, to 
expanding range of customer preferences, to
expanding range of customer preferences, to 
expanding range of customer preferences, to 
(cid:57) (cid:44) (cid:3) (cid:373) (cid:3) (cid:38) (cid:43) (cid:36) (cid:44) (cid:53) (cid:48) (cid:36) (cid:49) (cid:366) (cid:54) (cid:3) (cid:47) (cid:40) (cid:55) (cid:55) (cid:40) (cid:53)
name just a few. And litigation, unfortunately, is 
name just a few. And litigation, unfortunately, is 
name just a few. And litigation, unfortunately, is
name just a few. And litigation, unfortunately, is 
prevalent throughout the healthcare industry.
prevalent throughout the healthcare industry.
prevalent throughout the healthcare industry.
prevalent throughout the healthcare industry.
These kinds of external factors can impact any
These kinds of external factors can impact any
These kinds of external factors can impact any
These kinds of external factors can impact any
business’ brand, reputation, and business model,
business’ brand, reputation, and business model,
business’ brand, reputation, and business model,
business’ brand, reputation, and business model,
so in partnership with our Board of Directors,
so in partnership with our Board of Directors,
so in partnership with our Board of Directors,
so in partnership with our Board of Directors,
executive committee, and leadership teams 
executive committee, and leadership teams 
executive committee, and leadership teams
executive committee, and leadership teams 
across the Company, we look to mitigate these
across the Company, we look to mitigate these
across the Company, we look to mitigate these
across the Company, we look to mitigate these
kinds of external risk factors wherever possible. 
kinds of external risk factors wherever possible.
kinds of external risk factors wherever possible. 
kinds of external risk factors wherever possible. 
Additionally, I want to emphasize that product 
Additionally, I want to emphasize that product 
Additionally, I want to emphasize that product
Additionally, I want to emphasize that product 
quality and safety are not only top business 
quality and safety are not only top business 
quality and safety are not only top business
quality and safety are not only top business 
priorities for Johnson & Johnson, they are 
priorities for Johnson & Johnson, they are 
priorities for Johnson & Johnson, they are
priorities for Johnson & Johnson, they are 
also core obligations embodied in Our Credo.
also core obligations embodied in Our Credo.
also core obligations embodied in Our Credo.
also core obligations embodied in Our Credo.
Across every Johnson & Johnson business, we 
Across every Johnson & Johnson business, we 
Across every Johnson & Johnson business, we
Across every Johnson & Johnson business, we 
apply a scientific, evidence-based approach in 
apply a scientific, evidence-based approach in 
apply a scientific, evidence-based approach in
apply a scientific, evidence-based approach in 
decisions about the research, marketing and
decisions about the research, marketing and
decisions about the research, marketing and
decisions about the research, marketing and
use of our products. Many of our brands and
use of our products. Many of our brands and
use of our products. Many of our brands and
use of our products. Many of our brands and
products have been trusted by consumers for 
products have been trusted by consumers for 
products have been trusted by consumers for
products have been trusted by consumers for 
decades, and when the safety of our products
decades, and when the safety of our products
decades, and when the safety of our products
decades, and when the safety of our products
is challenged, we will continue to defend them.
is challenged, we will continue to defend them.
is challenged, we will continue to defend them.
is challenged, we will continue to defend them.
We have a legacy of working hard to earn our
We have a legacy of working hard to earn our
We have a legacy of working hard to earn our
We have a legacy of working hard to earn our
customers’ trust and working equally hard to keep
customers’ trust and working equally hard to keep
customers’ trust and working equally hard to keep
customers’ trust and working equally hard to keep
it—this commitment will always remain intact. 
it—this commitment will always remain intact.
it—this commitment will always remain intact. 
it—this commitment will always remain intact. 
We are confident in our ability to lead with
We are confident in our ability to lead with
We are confident in our ability to lead with
We are confident in our ability to lead with
certainty and to responsibly navigate our way 
certainty and to responsibly navigate our way 
certainty and to responsibly navigate our way
certainty and to responsibly navigate our way 
through these potential challenges. And because 
through these potential challenges. And because 
through these potential challenges. And because
through these potential challenges. And because 
we are committed to thriving in this change 
we are committed to thriving in this change 
we are committed to thriving in this change
we are committed to thriving in this change 
environment, our goal is not merely to adapt 
environment, our goal is not merely to adapt
environment, our goal is not merely to adapt 
environment, our goal is not merely to adapt 
to change, but to be the catalyst for needed 
to change, but to be the catalyst for needed 
to change, but to be the catalyst for needed
to change, but to be the catalyst for needed 
change. We also lead with certainty because 
change. We also lead with certainty because 
change. We also lead with certainty because
change. We also lead with certainty because 
we are in the business of caring for the world all
we are in the business of caring for the world all
we are in the business of caring for the world all
we are in the business of caring for the world all
day, every day. Guided by Our Credo, we have
day, every day. Guided by Our Credo, we have
day, every day. Guided by Our Credo, we have
day, every day. Guided by Our Credo, we have
a solid financial foundation, a strong strategic
a solid financial foundation, a strong strategic
a solid financial foundation, a strong strategic
a solid financial foundation, a strong strategic
framework, an innovation mindset, a performance
framework, an innovation mindset, a performance
framework, an innovation mindset, a performance
framework, an innovation mindset, a performance
driven culture and a very bright future focused 
driven culture and a very bright future focused
driven culture and a very bright future focused 
driven culture and a very bright future focused 
on advancing the health and well-being of all our 
on advancing the health and well-being of all our
on advancing the health and well-being of all our 
on advancing the health and well-being of all our 
stakeholders—today and for generations to come.
stakeholders—today and for generations to come.
stakeholders—today and for generations to come.
stakeholders—today and for generations to come.
Our People, Passion and Purpose
Our People, Passion and Purpose
Our People, Passion and Purpose
Our People, Passion and Purpose
I’ve often noted healthcare is an industry that
I’ve often noted healthcare is an industry that
I’ve often noted healthcare is an industry that
I’ve often noted healthcare is an industry that
attracts very special people. While they want
attracts very special people. While they want
attracts very special people. While they want
attracts very special people. While they want
the opportunity to build a meaningful career,
the opportunity to build a meaningful career,
the opportunity to build a meaningful career,
the opportunity to build a meaningful career,
they also want to be a part of something truly 
they also want to be a part of something truly
they also want to be a part of something truly 
they also want to be a part of something truly 
significant that makes an important difference in
significant that makes an important difference in
significant that makes an important difference in
significant that makes an important difference in
people’s lives. Fortunately, we have the very best
people’s lives. Fortunately, we have the very best
people’s lives. Fortunately, we have the very best
people’s lives. Fortunately, we have the very best
of these special people at the Johnson & Johnson
of these special people at the Johnson & Johnson
of these special people at the Johnson & Johnson
of these special people at the Johnson & Johnson
Family of Companies. And I believe our culture 
Family of Companies. And I believe our culture
Family of Companies. And I believe our culture 
Family of Companies. And I believe our culture 
of diversity and inclusion brings out the best that
of diversity and inclusion brings out the best that
of diversity and inclusion brings out the best that
of diversity and inclusion brings out the best that
our Johnson & Johnson colleagues have to offer. 
our Johnson & Johnson colleagues have to offer.
our Johnson & Johnson colleagues have to offer. 
our Johnson & Johnson colleagues have to offer. 
Today, we have approximately 135,000 global 
Today, we have approximately 135,000 global 
Today, we have approximately 135,000 global
Today, we have approximately 135,000 global 
employees, united by a shared commitment 
employees, united by a shared commitment
employees, united by a shared commitment 
employees, united by a shared commitment 

--- Page 9 ---
and a common purpose that aspires to create 
and a common purpose that aspires to create 
and a common purpose that aspires to create
and a common purpose that aspires to create 
a world without disease and with greater 
a world without disease and with greater
a world without disease and with greater 
a world without disease and with greater 
access to quality healthcare—life-saving
access to quality healthcare—life-saving
access to quality healthcare—life-saving
access to quality healthcare—life-saving
medicines, life-changing medical solutions and 
medicines, life-changing medical solutions and 
medicines, life-changing medical solutions and
medicines, life-changing medical solutions and 
life-enhancing consumer products. All of us 
life-enhancing consumer products. All of us 
life-enhancing consumer products. All of us
life-enhancing consumer products. All of us 
maintain a persistent focus on developing and
maintain a persistent focus on developing and
maintain a persistent focus on developing and
maintain a persistent focus on developing and
delivering quality and safe products and services. 
delivering quality and safe products and services. 
delivering quality and safe products and services.
delivering quality and safe products and services. 
Delivering on the promises of our brands is both
Delivering on the promises of our brands is both
Delivering on the promises of our brands is both
Delivering on the promises of our brands is both
a personal and professional commitment. 
a personal and professional commitment.
a personal and professional commitment. 
a personal and professional commitment. 
This is demonstrated in the tireless efforts 
This is demonstrated in the tireless efforts 
This is demonstrated in the tireless efforts
This is demonstrated in the tireless efforts
and relentless passion that drive our ambition 
and relentless passion that drive our ambition 
and relentless passion that drive our ambition
and relentless passion that drive our ambition 
to reach the next frontier of cancer care,
to reach the next frontier of cancer care,
to reach the next frontier of cancer care,
to reach the next frontier of cancer care,
continue to combat Ebola and HIV, bring healthy
continue to combat Ebola and HIV, bring healthy
continue to combat Ebola and HIV, bring healthy
continue to combat Ebola and HIV, bring healthy
vision to people everywhere, create a world
vision to people everywhere, create a world
vision to people everywhere, create a world
vision to people everywhere, create a world
free from tuberculosis, reduce our carbon 
free from tuberculosis, reduce our carbon 
free from tuberculosis, reduce our carbon
free from tuberculosis, reduce our carbon 
footprint, improve our product sustainability
footprint, improve our product sustainability
footprint, improve our product sustainability
footprint, improve our product sustainability
and reimagine the way that care is delivered, 
and reimagine the way that care is delivered,
and reimagine the way that care is delivered, 
and reimagine the way that care is delivered, 
while also expanding access for the world’s most 
while also expanding access for the world’s most 
while also expanding access for the world’s most
while also expanding access for the world’s most 
vulnerable populations. Johnson & Johnson
vulnerable populations. Johnson & Johnson
vulnerable populations. Johnson & Johnson
vulnerable populations. Johnson & Johnson
made Fortune’s “Change the World List” again 
made Fortune’s “Change the World List” again
made Fortune’s “Change the World List” again 
made Fortune’s “Change the World List” again 
in 2018, in recognition of our efforts to help train 
in 2018, in recognition of our efforts to help train
in 2018, in recognition of our efforts to help train 
in 2018, in recognition of our efforts to help train 
surgeons, paramedics and other healthcare
surgeons, paramedics and other healthcare
surgeons, paramedics and other healthcare
surgeons, paramedics and other healthcare
providers globally through our Johnson & 
providers globally through our Johnson & 
providers globally through our Johnson & 
providers globally through our Johnson & 
Johnson Institute and other care programs.
Johnson Institute and other care programs.
Johnson Institute and other care programs.
Johnson Institute and other care programs.
Our goal is to lead by example, by cultivating 
Our goal is to lead by example, by cultivating 
Our goal is to lead by example, by cultivating
Our goal is to lead by example, by cultivating 
the world’s healthiest, most productive and most
the world’s healthiest, most productive and most
the world’s healthiest, most productive and most
the world’s healthiest, most productive and most
engaged workforce. I believe this is critical for 
engaged workforce. I believe this is critical for
engaged workforce. I believe this is critical for 
engaged workforce. I believe this is critical for 
operating a healthy and successful business. And
operating a healthy and successful business. And
operating a healthy and successful business. And
operating a healthy and successful business. And
this is how we will deliver and ensure that another 
this is how we will deliver and ensure that another 
this is how we will deliver and ensure that another
this is how we will deliver and ensure that another
133 years of quality healthcare is within reach of 
133 years of quality healthcare is within reach of 
133 years of quality healthcare is within reach of
133 years of quality healthcare is within reach of 
everyone, everywhere.
everyone, everywhere.
everyone, everywhere.
everyone, everywhere.
uman HHHealthealthealth
n Education in HHHuman 
AAAn Education in
An Education in Human Health
uman
n Education in
I am as excited and encouraged today, as I was
I am as excited and encouraged today, as I was
I am as excited and encouraged today, as I was
I am as excited and encouraged today, as I was
on the day I started as CEO of this Company and
on the day I started as CEO of this Company and
on the day I started as CEO of this Company and
on the day I started as CEO of this Company and
accepted the responsibilities that come with it.
accepted the responsibilities that come with it.
accepted the responsibilities that come with it.
accepted the responsibilities that come with it.
Throughout my career at Johnson & Johnson, I 
Throughout my career at Johnson & Johnson, I 
Throughout my career at Johnson & Johnson, I
Throughout my career at Johnson & Johnson, I 
have been very fortunate to learn this business
have been very fortunate to learn this business
have been very fortunate to learn this business
have been very fortunate to learn this business
from the perspective of a company that is built 
from the perspective of a company that is built
from the perspective of a company that is built 
from the perspective of a company that is built 
on the belief in the transformative possibilities 
on the belief in the transformative possibilities 
on the belief in the transformative possibilities
on the belief in the transformative possibilities 
of human ingenuity and personal caring. The 
of human ingenuity and personal caring. The 
of human ingenuity and personal caring. The
of human ingenuity and personal caring. The 
world has been the campus for my education in 
world has been the campus for my education in
world has been the campus for my education in 
world has been the campus for my education in 
human health, as it has been for my Johnson & 
human health, as it has been for my Johnson & 
human health, as it has been for my Johnson & 
human health, as it has been for my Johnson & 
Johnson colleagues. I deeply appreciate the
Johnson colleagues. I deeply appreciate the
Johnson colleagues. I deeply appreciate the
Johnson colleagues. I deeply appreciate the
guiding support of our highly accomplished 
guiding support of our highly accomplished 
guiding support of our highly accomplished
guiding support of our highly accomplished 
Board of Directors and continue to be proud and
Board of Directors and continue to be proud and
Board of Directors and continue to be proud and
Board of Directors and continue to be proud and
humbled as I work side by side with this team of
humbled as I work side by side with this team of
humbled as I work side by side with this team of
humbled as I work side by side with this team of
impressive executive leaders, whose partnership
impressive executive leaders, whose partnership
impressive executive leaders, whose partnership
impressive executive leaders, whose partnership
and expertise motivate me and all our Johnson 
and expertise motivate me and all our Johnson 
and expertise motivate me and all our Johnson
and expertise motivate me and all our Johnson 
& Johnson colleagues every day in our shared
& Johnson colleagues every day in our shared
& Johnson colleagues every day in our shared
& Johnson colleagues every day in our shared
commitment to advance health for humanity.
commitment to advance health for humanity.
commitment to advance health for humanity.
commitment to advance health for humanity.
We have approximately 135,000 global 
employees, united by a shared commitment 
and a common purpose that aspires to 
create a world without disease and with 
greater access to quality healthcare.
My optimism for the future is inspired by the
My optimism for the future is inspired by the
My optimism for the future is inspired by the
My optimism for the future is inspired by the
rapid and continuous improvements in the 
rapid and continuous improvements in the
rapid and continuous improvements in the 
rapid and continuous improvements in the 
condition of human health and the increasing
condition of human health and the increasing
condition of human health and the increasing
condition of human health and the increasing
possibilities for healthcare in the world. Most
possibilities for healthcare in the world. Most
possibilities for healthcare in the world. Most
possibilities for healthcare in the world. Most
importantly, we have the amazing privilege 
importantly, we have the amazing privilege
importantly, we have the amazing privilege 
importantly, we have the amazing privilege 
of touching lives around the world every
of touching lives around the world every
of touching lives around the world every
of touching lives around the world every
day—from babies taking their first breath to
day—from babies taking their first breath to
day—from babies taking their first breath to
day—from babies taking their first breath to
baby boomers taking a breath after doing the 
baby boomers taking a breath after doing the 
baby boomers taking a breath after doing the
baby boomers taking a breath after doing the 
Johnson & Johnson Official 7 Minute Workout.
Johnson & Johnson Official 7 Minute Workout.
Johnson & Johnson Official 7 Minute Workout.
Johnson & Johnson Official 7 Minute Workout.
We also have the pleasure of serving patients 
We also have the pleasure of serving patients 
We also have the pleasure of serving patients
We also have the pleasure of serving patients 
and consumers everywhere on Earth—people
and consumers everywhere on Earth—people
and consumers everywhere on Earth—people
and consumers everywhere on Earth—people
who put their trust in our Johnson & Johnson
who put their trust in our Johnson & Johnson
who put their trust in our Johnson & Johnson
who put their trust in our Johnson & Johnson
brands. We never forget the responsibility that
brands. We never forget the responsibility that
brands. We never forget the responsibility that
brands. We never forget the responsibility that
comes with this trust. And we never forget our 
comes with this trust. And we never forget our 
comes with this trust. And we never forget our
comes with this trust. And we never forget our 
essential partnership with our shareholders
essential partnership with our shareholders
essential partnership with our shareholders
essential partnership with our shareholders
who support our mission and help us pursue
who support our mission and help us pursue
who support our mission and help us pursue
who support our mission and help us pursue
a noble purpose. While the challenges are 
a noble purpose. While the challenges are 
a noble purpose. While the challenges are
a noble purpose. While the challenges are 
great, the rewards are even greater. I can’t 
great, the rewards are even greater. I can’t 
great, the rewards are even greater. I can’t
great, the rewards are even greater. I can’t 
imagine a better or more fulfilling calling!
imagine a better or more fulfilling calling!
imagine a better or more fulfilling calling!
imagine a better or more fulfilling calling!
I offer my sincere thanks to all of you for this 
I offer my sincere thanks to all of you for this
I offer my sincere thanks to all of you for this 
I offer my sincere thanks to all of you for this 
great privilege, opportunity and experience.
great privilege, opportunity and experience.
great privilege, opportunity and experience.
great privilege, opportunity and experience.
(cid:54)(cid:76)(cid:81)(cid:70)(cid:72)(cid:85)(cid:72)(cid:79)(cid:92)(cid:15)
(cid:54)(cid:76)(cid:81)(cid:70)(cid:72)(cid:85)(cid:72)(cid:79)(cid:92)(cid:15)
(cid:54)(cid:76)(cid:81)(cid:70)(cid:72)(cid:85)(cid:72)(cid:79)(cid:92)(cid:15)
(cid:54)(cid:76)(cid:81)(cid:70)(cid:72)(cid:85)(cid:72)(cid:79)(cid:92)(cid:15)
Alex Gorsky
Alex Gorsky
Alex Gorsky
Alex Gorsky
Chairman and Chief Executive Officer
Chairman and Chief Executive Officer
Chairman and Chief Executive Officer
Chairman and Chief Executive Officer
Johnson & Johnson
Johnson & Johnson
Johnson & Johnson
Johnson & Johnson
*Non-GAAP measures: Free cash flow is defined as operating cash flow less capital spending. Adjusted operational earnings growth excludes special items, intangible 
(cid:68)(cid:86)(cid:86)(cid:72)(cid:87) (cid:68)(cid:80)(cid:82)(cid:85)(cid:87)(cid:76)(cid:93)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81) (cid:72)(cid:91)(cid:83)(cid:72)(cid:81)(cid:86)(cid:72) (cid:68)(cid:81)(cid:71) (cid:87)(cid:75)(cid:72) (cid:72)(cid:609)(cid:72)(cid:70)(cid:87) (cid:82)(cid:73) (cid:87)(cid:85)(cid:68)(cid:81)(cid:86)(cid:79)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:68)(cid:79) (cid:70)(cid:88)(cid:85)(cid:85)(cid:72)(cid:81)(cid:70)(cid:92)(cid:17) (cid:50)(cid:83)(cid:72)(cid:85)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:68)(cid:79) (cid:86)(cid:68)(cid:79)(cid:72)(cid:86) (cid:74)(cid:85)(cid:82)(cid:90)(cid:87)(cid:75) (cid:72)(cid:91)(cid:70)(cid:79)(cid:88)(cid:71)(cid:72)(cid:86) (cid:87)(cid:75)(cid:72) (cid:72)(cid:609)(cid:72)(cid:70)(cid:87) (cid:82)(cid:73) (cid:87)(cid:85)(cid:68)(cid:81)(cid:86)(cid:79)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:68)(cid:79) (cid:70)(cid:88)(cid:85)(cid:85)(cid:72)(cid:81)(cid:70)(cid:92)(cid:17) (cid:54)(cid:72)(cid:72) (cid:49)(cid:82)(cid:81)(cid:16)(cid:42)(cid:36)(cid:36)(cid:51) (cid:53)(cid:72)(cid:70)(cid:82)(cid:81)(cid:70)(cid:76)(cid:79)(cid:76)(cid:68)-
tions of Free cash flow and Operational sales growth excluding acquisitions and divestitures for the Medical Devices segment in this Annual Report.
(cid:49)(cid:50)(cid:55)(cid:40)(cid:3)(cid:53)(cid:40)(cid:42)(cid:36)(cid:53)(cid:39)(cid:44)(cid:49)(cid:42) (cid:41)(cid:50)(cid:53)(cid:58)(cid:36)(cid:53)(cid:39)(cid:569)(cid:47)(cid:50)(cid:50)(cid:46)(cid:44)(cid:49)(cid:42) (cid:54)(cid:55)(cid:36)(cid:55)(cid:40)(cid:48)(cid:40)(cid:49)(cid:55)(cid:54)(cid:3)
This letter contains forward-looking statements relating to, among other things, future operating and financial performance, product development, market position
and business strategy. The reader is cautioned not to rely on these statements, which are based on current expectations of future events. For important information 
about these statements, including the risks, uncertainties and other factors that could cause actual results to vary materially from the assumptions, expectations and
projections expressed in any forward-looking statements, the readers should review the enclosed Annual Report on Form 10-K for the fiscal year ended December 30, 
(cid:21)(cid:19)(cid:20)(cid:27)(cid:15) (cid:76)(cid:81)(cid:70)(cid:79)(cid:88)(cid:71)(cid:76)(cid:81)(cid:74) (cid:76)(cid:81) (cid:87)(cid:75)(cid:72) (cid:86)(cid:72)(cid:70)(cid:87)(cid:76)(cid:82)(cid:81)(cid:86) (cid:70)(cid:68)(cid:83)(cid:87)(cid:76)(cid:82)(cid:81)(cid:72)(cid:71) (cid:368)(cid:38)(cid:68)(cid:88)(cid:87)(cid:76)(cid:82)(cid:81)(cid:68)(cid:85)(cid:92) (cid:49)(cid:82)(cid:87)(cid:72) (cid:53)(cid:72)(cid:74)(cid:68)(cid:85)(cid:71)(cid:76)(cid:81)(cid:74) (cid:41)(cid:82)(cid:85)(cid:90)(cid:68)(cid:85)(cid:71)(cid:16)(cid:47)(cid:82)(cid:82)(cid:78)(cid:76)(cid:81)(cid:74) (cid:54)(cid:87)(cid:68)(cid:87)(cid:72)(cid:80)(cid:72)(cid:81)(cid:87)(cid:86)(cid:369) (cid:68)(cid:81)(cid:71) (cid:368)(cid:44)(cid:87)(cid:72)(cid:80) (cid:20)(cid:36)(cid:17) (cid:53)(cid:76)(cid:86)(cid:78) (cid:41)(cid:68)(cid:70)(cid:87)(cid:82)(cid:85)(cid:86)(cid:17)(cid:369) (cid:45)(cid:82)(cid:75)(cid:81)(cid:86)(cid:82)(cid:81) (cid:9) (cid:45)(cid:82)(cid:75)(cid:81)(cid:86)(cid:82)(cid:81) (cid:71)(cid:82)(cid:72)(cid:86) (cid:81)(cid:82)(cid:87) (cid:88)(cid:81)(cid:71)(cid:72)(cid:85)(cid:87)(cid:68)(cid:78)(cid:72)
to update any forward-looking statement as a result of new information or future events or developments.

--- Page 11 ---
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K
ANNUAL REPORT PURSUANT TO SECTION 13 OF
THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 30, 2018
Commission file number 1-3215
JOHNSON & JOHNSON
(Exact name of registrant as specified in its charter)
New Jersey
(State of incorporation)
22-1024240
(I.R.S. Employer Identification No.)
One Johnson & Johnson Plaza
New Brunswick, New Jersey
(Address of principal executive offices)
08933
(Zip Code)
Registrant’s telephone number, including area code: (732) 524-0400
SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT
Title of each class
Common Stock, Par Value $1.00
4.75% Notes Due November 2019
0.250% Notes Due January 2022
0.650% Notes Due May 2024
5.50% Notes Due November 2024
1.150% Notes Due November 2028
1.650% Notes Due May 2035
Name of each exchange on which registered
New York Stock Exchange
New York Stock Exchange
New York Stock Exchange
New York Stock Exchange
New York Stock Exchange
New York Stock Exchange
New York Stock Exchange
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities
Act. Yes Í No ‘
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange
Act. Yes ‘ No Í
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the
Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such
reports), and (2) has been subject to such filing requirements for the past 90 days. Yes Í No ‘
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted
pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was
required to submit such files). Yes Í No ‘
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and
will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by
reference in Part III of this Form 10-K or any amendment to this Form 10-K. ‘
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller
reporting company, or emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller
reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer Í Accelerated filer ‘ Non-accelerated filer ‘ Smaller reporting company ‘
Emerging growth company ‘
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ‘
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange
Act). Yes ‘ No Í
The aggregate market value of the Common Stock held by non-affiliates computed by reference to the price at which the
Common Stock was last sold as of the last business day of the registrant’s most recently completed second fiscal quarter
was approximately $325 billion.
On February 15, 2019, there were 2,663,138,579 shares of Common Stock outstanding.
DOCUMENTS INCORPORATED BY REFERENCE
Parts I and III:
Portions of registrant’s proxy statement for its 2019 annual meeting of shareholders filed within
120 days after the close of the registrant’s fiscal year (the “Proxy Statement”), are incorporated by
reference to this report on Form 10-K (this “Report”).

--- Page 12 ---
PART I
Item
1
Business
General
Segments of Business
Geographic Areas
Raw Materials
Patents
Trademarks
Seasonality
Competition
Environment
Regulation
Available Information
1A. Risk Factors
1B. Unresolved Staff Comments
2
3
4
Properties
Legal Proceedings
Mine Safety Disclosures
Executive Officers of the Registrant
5
Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of
PART II
Equity Securities
Selected Financial Data
Management’s Discussion and Analysis of Results of Operations and Financial Condition
6
7
7A. Quantitative and Qualitative Disclosures About Market Risk
8
9
9A. Controls and Procedures
9B. Other Information
Financial Statements and Supplementary Data
Changes in and Disagreements With Accountants on Accounting and Financial Disclosure
10
11
12
13
14
15
16
PART III
Directors, Executive Officers and Corporate Governance
Executive Compensation
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder
Matters
Certain Relationships and Related Transactions, and Director Independence
Principal Accountant Fees and Services
PART IV
Exhibits and Financial Statement Schedules
Form 10-K Summary
Signatures
Exhibit Index
Page
1
1
1
2
2
2
3
3
3
3
3
4
4
9
9
10
10
11
13
14
15
35
35
102
102
102
103
103
103
104
104
105
105
106
107
